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The present doctoral thesis focuses on two articles which are embedded in the field of 
precision mental health and treatment selection. Study 1 examined if model determined 
treatment allocation to cognitive behavioral therapy (CBT) or CBT with integrated exposure 
and emotion-focused elements (CBT-EE) results in better treatment outcomes while using 
important predictors found for each intervention. Study 2 investigated important predictors in 
routine care and blended internet- and face-to-face CBT in secondary care, as well as   
treatment outcomes for treatment allocation using this predictive information. Both studies 
use a Bayesian approach called Bayesian Model Averaging (BMA) and the Personalized 
Advantage Index (PAI) for their statistical analyses. After an introduction to the Generic 
Model of Psychotherapy, the development of process and outcome research and the thematic 
field of treatment selection and precision medicine, the individual articles will be described 
and critically reflected in more detail. Possibilities and limits of predicting the optimal 
treatment for an individual based on algorithms are discussed based on the results of the two 
studies. Taken together, the two studies provide an important contribution to psychotherapy 
research as the feasibility of treatment selection using BMA and PAI is shown. Last but not 
least, implications for future research are discussed and an example of how treatment 
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1 General introduction 
 
Almost half of all people around the globe meet the criteria of a clinically relevant 
mental disorder at least once in their lives. Approximately one in three suffer from an anxiety 
disorder once in their lives and almost one in six suffer from a depressive episode (Kessler et 
al., 2005). According to the World Health Organization, 300 million people globally suffer 
from major depressive disorder (MDD) and by 2030 it will be one of the leading causes of the 
global burden of disease (Mathers & Loncar, 2006; World Health Organization, 2018). It is 
one of the most common problems seen in clinical practice and it is associated with a great 
deal of suffering and societal costs (World Health Organization, 2008). One reason for this is 
the chronic-intermittent course that MDD and anxiety disorders can take resulting in a 
sustained impact on the quality of life (Penninx et al., 2011). Furthermore, it is assumed that 
up to 20-25% of MDD patients are at risk for chronic depression (Dinga et al., 2018).  
In order to deal with the increasing prevalence of mental disorders worldwide, 
appropriate treatment options are needed. Well established treatment approaches for MDD are 
cognitive behavioral therapy (CBT), interpersonal psychotherapy (IPT) and antidepressant 
medication (ADM). Although these approaches are well studied and have shown to be 
efficacious (Cuijpers et al., 2013; Hollon, Cohen, Singla, & Andrews, 2019), a high 
percentage of people that suffer from MDD or anxiety disorders are either not in treatment or 
do not benefit from it as much as expected (Cohen & DeRubeis, 2018). As a result, there are 
low treatment response rates and high dropout rates in treatments for depression (Cuijpers & 
Christensen, 2017; Hollon et al., 2019; Lemmens et al., 2019). Different factors can be held 
accountable for this. First, accessibility and availability of adequate treatment options are 
limited (Cavanagh, 2014). Second, one needs to recognize that no single treatment is likely to 





and new technologies and advances in psychotherapy research have a great potential to 
improve overall response rates and accessibility of psychological treatments.  
1.1 Process outcome research 
 
Over the years, psychotherapy research as we know it now has come a long way and it 
continues to be characterized by new developments and changing emphases (Lambert, 2013). 
Historically, it underwent four developmental phases with each of them addressing a 
fundamental question. The legitimation phase and the second phase, the competition phase 
answer the questions “Is psychotherapy effective” and respectively “Which form of 
psychotherapy is better?”. The prescriptive psychotherapy phase addresses the question 
“Which form of psychotherapy is indicated for whom?” and the last phase is called the 
process-research phase which looks at the mechanism of change in psychotherapy (Grawe, 
1997).  
Although the studies that are being discussed in this thesis focus on the prescriptive 
phase, it is important to look at the bigger picture, namely the process-outcome research 
because it offers a potential framework on how to answer the fundamental question of the 
prescriptive phase. Process-outcome research is one field in psychotherapy research that 
measures process variables and tests whether they relate to therapy outcome (Hill & Corbett, 
1993; Orlinsky & Howard, 1986; Orlinsky, Ronnestad, & Willutzki, 2004; Timulak, 2008). 
First, it is essential to define what is meant by process and outcome. Process can be defined as 
everything that happens in the therapy sessions, thus therapist and client behaviors but also 
the interaction between the two. This is only one possible definition of process because there 
is great variability in the meaning attached to it (Orlinsky et al., 2004). The outcome refers to 
the changes that occur as a result of the psychotherapeutic process (Hill & Corbett, 1993; 





therapy or whether smaller outcomes in and between sessions should be defined as such as 
well (Greenberg & Pinsof, 1986).  
Similar to the developmental process of psychotherapy research, process-outcome 
research developed through different stages as well (Orlinsky et al., 2004). The initial phase 
(1920-1950) had the goal to establish scientific research into psychotherapy (Bergin, 1971). In 
a second phase, treatment monitoring was established through the recording of therapy 
sessions. Since 1960, the use of diagnostic questionnaires and rating scales was established 
with the aim to install scientific accuracy (Orlinsky et al., 2004). The third historical phase of 
process-outcome research can be described as one of expansion, differentiation, and 
organization (Orlinsky & Russell, 1994). This phase is especially characterized by the first 
meta-analysis to demonstrate the effectiveness of psychotherapy (Smith, Glass, & Miller, 
1980). According to this meta-analysis, 80% of patients are better off after treatment 
compared to an untreated sample (Hill & Corbett, 1993). The greatest accomplishment of this 
phase was the introduction of the effect size as the universal comparative parameter. This 
allowed for all researchers to integrate and compare their findings (Orlinsky et al., 2004). 
Moreover, there was a revival of interest in the working alliance concept which remains 
strong up to today (Horvath & Greenberg, 1994). The working alliance is still seen as one of 
the core contributions to a successful therapy outcome and is one of the most researched 
variables in psychotherapy research (Flückiger, Del Re, Wampold, & Horvath, 2018). 
Furthermore, the method “task analysis” as a way to track and analyze in-session events that 
can be used as markers for therapeutically significant events was introduced (Rice & 
Greenberg, 1984). The fourth and last phase of the development of process-outcome research 
started in around 1985 and was dominated by consolidation, standardization and elaboration. 
The results of several long-term studies were published and with regard to standardization, 





research (Bothwell, Greene, Podolsky, & Jones, 2016). Elaboration in this phase stands for 
the use of new statistical methods that allow for more sophisticated analyses (Kraemer & 
Thiemann, 1989). Moreover, this phase is characterized by critique, innovation and 
controversy. For example, the criticism of group comparison research designs led to a shift 
from treatment focused research to patient focused research (Howard, Moras, Brill, 
Martinovich, & Lutz, 1996; Orlinsky et al., 2004). Furthermore, the use of qualitative 
methods was highly encouraged because the integration of quantitative and qualitative 
methods retains the richness of data (Hill & Corbett, 1993; Orlinsky et al., 2004). One can say 
that we are still in this last phase as the constructs named above still play an important role in 
process-outcome research today. To date, more than 2000 process outcome studies have been 
published including several comprehensive reviews (Llewelyn, Macdonald, & Doorn, 2016). 
1.2 The Generic Model of Psychotherapy 
 
 With the growing number of process outcome studies, Orlinsky and Howard thought 
of a model that integrates the results of these studies called the “Generic Model of 
Psychotherapy” (Orlinsky & Howard, 1987). It is conceived as a transtheoretical frame for 
integrating various empirical findings and it offers a comprehensive framework in which 
clinical theories of psychotherapy can be compared and combined (Orlinsky, 2009). The 
Generic Model of Psychotherapy integrates 2354 findings of almost 500 psychotherapy 
studies that examine the relationship of a process variable with an outcome variable. The goal 
was to create a research theory or in other words a research-based metatheory of 
psychotherapy. It links clinical practice theories or treatment models independent of their 
theoretical background which ultimately leads to a great source of guidance for empirical 
investigations. Furthermore, it acts as a conceptual framework that guides psychotherapy 
researchers in the development and implementation of studies. Most importantly, the Generic 





different approaches to psychotherapy (Orlinsky, 2009; Orlinsky & Howard, 1987; Orlinsky 
et al., 2004).  
 The Generic Model of Psychotherapy is shown in Figure 1. It consists of three levels 
of distinction. First, the input is the context in which psychotherapy takes place. It is 
important to acknowledge that psychotherapy is embedded in the social context of the patient. 
One cannot say the patient is in therapy but one has to say that the therapy takes place in the 
life of the patient and is thus a part of it. The variables included in the input have the potential 
to influence the process of psychotherapy. Second, the process is the key component of the 
model. It includes the interactions between the therapist and patient during therapy. The third 
level of distinction is the output which is the result of this process. The therapy has effects 
that go beyond the direct outcome for the patient. It has consequences for the environment of 






Figure 1. The Generic Model of Psychotherapy (Orlinsky & Howard, 1987). 
 
The heart of the model, the process includes five active psychotherapeutic processes 
and the component temporal patterns which was added to the model in later years when 





Each process category includes the role of the patient as well as the role of the therapist. The 
therapeutic contract represents the organizational aspect of therapy, e.g. therapy goals, the 
format and the rationale. It defines the norms of the participant’s roles as therapist and patient 
(Orlinsky et al., 2004). The therapeutic operations represent the technical aspect of 
psychotherapy in the form of the cycle of reciprocal role-specific behavior. Patient 
presentation leads to the expert understanding and as a result to the therapist intervention. The 
intervention of the therapist in turn leads to the cooperation of the patient. The interpersonal 
aspect of therapy is defined as the therapeutic bond which describes the quality of the 
involvement of the therapist and the patient and the respective interpersonal behavior. It 
includes a socio-emotional component as well as the working alliance. The fourth process 
category is the therapist’s and patient’s self-relatedness which stands for their intrapersonal 
behavior. The clinical aspect of therapy is shown in the in-session impacts. In-session impacts 
are immediate positive or negative impacts resulting from the therapeutic operations. The 
sixth category temporal patterns represents the sequential aspect of process. This can include 
sequelae of events and moments during the sessions, periods or stages in the treatment stage 
or temporal aspects of the whole treatment course. The first five categories are concurrent 
facets of the psychotherapeutic process and cannot be seen as distinct stages, thus they do not 
occur in the order named above but they are in a constant interaction with each other. Each 
form of psychotherapy includes an individual configuration of the process categories 
(Orlinsky et al., 2004).  
In the Generic Model of Psychotherapy, psychotherapy is viewed as a system of action 
that has individual and collective contexts that influence therapeutic processes in the form of 
input and, in turn, are influenced by therapeutic processes (output). Relationships of process 
variables and outcome variables that have shown to be robust findings included in the Generic 





patient, (3) cognitive and behavioral processes, (4) cooperation, (5) positive affect, (6) 
engagement, (7) openness and (8) articulateness. Hence, the active participation of the patient 
in the therapy seems to play an important role for a successful therapy. For the therapist, 
variables that showed a consistent relationship with the output are (1) problem actualization 
and confrontation, (2) interpretation and (3) paradox interventions. Furthermore, the 
therapeutic bond, appreciation and the length of therapy had a robust relationship to the output 
(Kolden & Howard, 1992; Orlinsky et al., 2004). 
To conclude, the results show that effective psychotherapy is more than a set of 
techniques but also more than a good therapeutic alliance. Moreover, the therapeutic outcome 
seems to be the result of the problems and resources of the patient in combination with the 
competencies and limits of the therapist. The Generic Model of Psychotherapy is a mean to 
help with the common issue of clinicians to respond to and integrate research findings into 
routine practice and for researchers to translate their findings into clinically useful 
recommendations for practice (Lambert, 2013).  
1.3 Precision medicine and treatment selection 
 
In Bern, Switzerland, there is a long tradition of differential psychotherapy research. 
As early as in the 1970s, Grawe was one of the first to consistently advocate differential 
psychotherapy, i.e. psychotherapy that takes into account important distinguishing 
characteristics of patients (Grawe, 1976). A couple of years later, in the beginning of the 
90ies, the results of the Bernese comparative treatment study were published. Again, 
differential psychotherapy research played a major role (Grawe, Caspar, & Ambühl, 1990). 
Four different types of therapy have been compared and numerous research questions have 
been examined. As an example, it was found that for individual broad spectrum behavior 





authors suggested that some patients may benefit from this therapy whereas others may not 
(Grawe et al., 1990).  
On an individual level, differential responses to treatments are not a scarcity (Simon & 
Perlis, 2010) because patients with depression vary in their treatment response and illness 
course (Cuijpers, Van Straten, Bohlmeijer, Hollon, & Andersson, 2010). In addition, patient 
characteristics can moderate the efficacy of different treatments (Fournier et al., 2009). 
Therefore, it is important to recognize that no treatment is likely to be the best for everyone 
thus no particular treatment works universally, across all patients and most interventions work 
well on some patients (Beutler & Harwood, 2002; Cohen & DeRubeis, 2018). But by finding 
for each individual the treatment that works best for him or her, it may be possible to improve 
the overall treatment response rates (Hollon et al., 2019). 
This is what guided Beutler and Harwood when they first introduced the term 
Prescriptive Psychotherapy and when they published their practical guide to systematic 
treatment selection (Beutler & Harwood, 2000). It is a detailed manual that provides a set of 
principles which can be used from multiple theoretical perspectives. Their goal was to be able 
to more effectively address the differences that exist between patients, since it is assumed that 
patients' reactions moderate treatment effects. Prescriptive Psychotherapy aims to match the 
setting, the patient and the therapist's dispositions with the patient's preferences. Its goal is to 
be able to make a clear treatment recommendation to the patient on which therapy is the best 
for him or her. According to Beutler and Harwood, the variables that interact most 
successfully with treatment are coping strategies, resistance, severity of the problem and the 
level of suffering (Beutler & Harwood, 2000). Furthermore, the term Systematic Treatment 
Selection (STS) is important to mention as it follows the ideas of Prescriptive Psychotherapy 
in the sense that it assumes that there is no treatment model that works well for all patients 





Beutler, Clarkin, & Bongar, 2000; Beutler, Harwood, Bertoni, & Thomann, 2006). STS has 
the goal to identify individual dispositional factors and the interventions that they most 
effectively correspond with while it is constructed around principles of behavior change 
irrespective of different therapeutic perspectives (Beutler et al., 2000; Beutler et al., 2006). 
Precision medicine has a long history of tailoring treatments to the specific needs and 
characteristics of a given patient (Katsnelson, 2013). It has shown to be especially successful 
in personalized treatment selection for cancer patients (Schwaederle et al., 2015). The use of 
algorithms to improve and support clinical decision-making in psychotherapy is growing as 
well (Cohen & DeRubeis, 2018; Hamburg & Collins, 2010). In fact, personalizing treatments 
for depression is one of the major challenges and promises for mental health research (Lopez-
Gomez et al., 2019). With regard to precision medicine in psychotherapy research, the 
following question plays an important role because it guides today’s efforts of personalizing 
treatments in psychotherapy: “In all its complexity, the question towards which all outcome 
research should ultimately be directed is the following: What treatment, by whom, is most 
effective for this individual with that specific problem, and under which set of 
circumstances?” (Paul, 1967, p. 117). This question is already very old and the fact that we 
have had surprisingly little resilient insight into it so far illustrates how difficult it is to find 
answers. 
 So how do clinicians and researchers know which patients will benefit from which 
treatments? A trial and error approach is used nowadays to find each patient a treatment 
modality that is helpful for him or her (Cuijpers & Christensen, 2017). As an example, 
patients often go through multiple antidepressants before an effective therapy regimen is 
identified (Rush et al., 2006). So far, different attempts at personalizing treatments have been 
made. Pharmacogenetics tried to improve pharmacotherapies with genotyping as 50% of the 





Holsboer, 2008). Furthermore, efforts have been made to divide depression into different 
subtypes that might respond differentially to different treatments (Baumeister & Gordon, 
2012). An approach that has become more and more popular is to compare two different 
treatments in an RCT and identify outcome moderators for each treatment while 
acknowledging individual patient differences (Kraemer, 2013). One of the earliest examples is 
the “matching factor” that combined the prescriptive value of different pre-treatment variables 
and the baseline symptom severity in a linear model that predicts symptom change (Barber & 
Muenz, 1996). Another example is the “nearest neighbors” technique where every patient’s 
outcome in each treatment is predicted from the average observed post-treatment score of 
patients who are similar to the index patient (Lutz et al., 2006). Advances like that and the 
heterogeneity of statistical analyses have shown promising results that have the potential to 
enhance personalized medicine in psychotherapy (Cohen & DeRubeis, 2018).     
1.4 The Personalized Advantage Index (PAI) 
 
The PAI approach is a treatment selection approach that uses machine learning and 
multivariable regression modeling to offer a solution for the challenges and problems in 
precision mental health. It identifies patients with certain characteristics for whom one 
treatment works better than another (Cohen & DeRubeis, 2018; Cohen, Kim, Van, Dekker, & 
Driessen, 2019). It then provides a quantitative estimate of how much one particular treatment 
is better for this patient than for another. The PAI is a promising approach to increase the 
likelihood of improving a patient’s mental health (DeRubeis, Cohen, et al., 2014). 
 This approach was first developed in 2011 by Robert DeRubeis and his team when they 
saw the results of an RCT that compared cognitive therapy (CT) with ADM for patients with 
depression. They found that on a group level, the treatments were equally effective but they 





al., 2005; Fournier et al., 2009). As an example, patients with comorbid personality disorder 
improved more with ADM than they did in CT whereas patients who were unemployed 
improved more in CT than in ADM. So how does a clinician use information from multiple 
conflicting predictors? According to early research, in cases like that, actuarial approaches to 
treatment selection seem to be superior to clinical judgement (Dawes, Faust, & Meehl, 1989). 
Others argue that clinical judgement makes a major contribution to therapy outcome and that 
it is essential in terms of constraints and resources of the patients (Caspar, 1997). The debate 
of which one is superior to the other cannot be answered definitively as strengths and 
difficulties can be found for both approaches (Meehl, 1954). The PAI may ultimately provide 
a solution for the challenge named above (Cohen & DeRubeis, 2018; DeRubeis, Cohen, et al., 
2014).  
The method can be used in any context where patients have been randomized to two or 
more treatment conditions that are equally effective on a group level. What is distinctive for 
the PAI approach is to identify pre-treatment variables that predict treatment outcome, either 
differential or for all treatments. In a next step, these variables are used to generate predictions 
for the treatment outcome of each patient for each treatment condition. As a result, each 
patient has a factual prediction, which is the treatment outcome for the treatment the patient 
actually received, and a counterfactual prediction for the treatment condition the patient did 
not receive. Thereupon, the prediction that indicates a better outcome is called the optimal 
treatment for that patient vs. the suboptimal treatment. The predicted difference of receiving 
the treatment with the greater predicted benefit versus the suboptimal treatment is an index of 
predicted advantage which is then called the PAI. Higher values of the PAI stand for a 
stronger predicted benefit (DeRubeis, Cohen, et al., 2014). When DeRubeis and his team first 
tested the PAI approach, they suggested to generate the predictions in the same model using a 





prediction is estimated is excluded from the model to avoid overfitting (DeRubeis, Cohen, et 
al., 2014; Efron & Gong, 1983). 
Since the introduction of the PAI, it has been applied to multiple data sets comparing 
different therapies. One study compared CT to IPT for patients with depression and found a 
PAI value of 8.9 BDI points. This means that patients who had received their optimal 
treatment had a BDI-II post-treatment score that was 8.9 points lower than if they had 
received the treatment suboptimal for them (Huibers et al., 2015). More recently, van 
Bronswijk and colleagues analyzed data from an RCT that compared CT with IPT for patients 
with depression as well and found a PAI of 5 points on the BDI-II. Interestingly, they 
compared a long-term PAI with the “regular” post-treatment PAI and found a weak 
correlation between the two meaning that the PAIs did not show consistency over time (van 
Bronswijk et al., 2019). When CBT was compared to psychodynamic therapy for patients 
with depression, a PAI of 1.6 points on the Hamilton-Depression-Rating Scale was found 
(Cohen et al., 2019). Moreover, the PAI has also been applied to data sets that compare two 
different treatments for patients with posttraumatic stress disorder (Deisenhofer et al., 2018; 
Keefe et al., 2018).  
Moreover, different variations of the PAI approach have been developed and tested that 
are aimed at differentiating placebo and antidepressant responders (Webb et al., 2019) and 
minimizing dropouts (Zilcha-Mano et al., 2016). A problem that comes with the heterogeneity 
of statistical approaches applied to variable and treatment selection is the lack of coherence in 
the variables found to predict treatment response in depression (Cohen & DeRubeis, 2018). 
The lack of replicability can be partially explained by the use of different variable selection 
methods with the same data set. They may lead to different conclusions about the predictors 
found to be important (Bleich, Kapelner, George, & Jensen, 2014) which in turn may lead to 





multivariable analyses are often statistically underpowered therefore spurious findings might 
be treated as clinically informative (Delgadillo & Gonzalez Salas Duhne, 2019; Luedtke, 
Sadikova, & Kessler, 2019).  
1.5 Prescriptive and prognostic predictors  
 
The relationship between a pre-treatment variable and the treatment outcome can be either 
a prognostic or a prescriptive one. A prognostic variable predicts treatment outcome 
irrespective of treatment condition. If the treatment response is predicted for only one 
treatment, only prognostic predictors can be found (Cohen & DeRubeis, 2018). In contrast, a 
prescriptive variable predicts a differential treatment response to two or more treatment 
modalities (Fournier et al., 2009). The latter is commonly called a moderator (Kraemer, 
Wilson, Fairburn, & Agras, 2002) and affects the strength or direction of differences in 
outcome (Baron & Kenny, 1986). When comparing two or more treatments, the prescriptive 
variables predict whether a patient benefits more from one treatment than another. However, 
the meaning of the term prescriptive is not just about making predictions, but about giving a 
clear treatment recommendation like Beutler and Harwood proposed when they introduced 
Prescriptive Psychotherapy (Beutler & Harwood, 2000). It is important to note that a variable 
found to be prognostic in one study can predict a differential treatment response, thus be 
prescriptive in another (Cohen & DeRubeis, 2018).    
There is little consistency in the literature regarding the variables that predict treatment 
outcome for patients with depression. Fournier and colleagues (2009) found the variables 
marriage, unemployment, and having experienced a greater number of recent life events to 
predict superior responses to CT compared to ADM. Another study found somatic 
complaints, paranoid symptoms, interpersonal self-sacrificing, attributional style focused on 





treatment outcome in CT compared to IPT (Huibers et al., 2015). Moreover, DeRubeis and 
colleagues (2014) found the absence of a comorbid personality disorder, marriage, 
employment, a greater number of stressful life events, and a greater number of prior 
antidepressant trials to predict favorable outcome in CBT compared to ADM. These examples 
show the diversity of variables that are being evaluated and the heterogeneity in the found 
results. Consequently, the use of these predictors for informed treatment selection becomes a 
difficult task for clinicians.   
1.6 Reference to the two studies presented 
 
The two studies of this doctoral thesis use the methodology of the PAI to advance the field 
of treatment selection in clinical psychology. Although the methodology is the same, the two 
studies provide a new contribution to the field of treatment selection for patients with 
depression as they both investigate treatment modalities that have not been evaluated yet in 
this sense. Study 1 compares an assimilative integration to a standard psychotherapy whereas 
Study 2 compares blended internet- and face-to-face treatment to routine care. Chapter 2 
presents sample, the data analytical strategy and the most important results of the two studies. 
Chapter 3 presents the limitations of the studies and problems in the field of treatment 
selection. Moreover, it discusses the future of treatment selection and personalizing 
treatments. Furthermore, the results of the two studies are put into the context of process 
outcome research and an example of the implementation of treatment selection in clinical 









2 Summary of the studies  
 
The following chapter presents the two studies of this doctoral thesis in a summarized form: 
Study 1: 
Friedl, N., Berger, T., Krieger, T., Caspar, F., & Grosse Holtforth, M. (2019). Using the 
Personalized Advantage Index for individual treatment allocation to cognitive behavioral 
therapy (CBT) or a CBT with integrated exposure and emotion-focused elements (CBT-
EE). Psychotherapy Research, 1-13. 
Study 2: 
Friedl, N., Krieger, T., Chevreul, K., Hazo, JB., Holtzmann, J., Hoogendoorn, M., 
Kleiboer, A., Mathiasen, K., Urech, A., Riper, H., & Berger, T., (in press). Using the 
Personalized Advantage Index for individual treatment allocation to blended treatment or 
treatment as usual for depression in secondary care.  
To provide a good overview, the studies are each divided into four sections and briefly 
summarized below: 1) goals and research questions of the study, (2) sample of the study, (3) 












2.1 Study 1: Using the Personalized Advantage Index for individual treatment 
allocation to cognitive behavioral therapy (CBT) or a CBT with integrated 
exposure and emotion-focused elements (CBT-EE).  
2.1.1 Goal of the study and research questions 
 
Chapter 1 referred to the need for personalized treatments for patients with depression 
because of the individual differences in the course of illness and the high variability in 
patient’s treatment response. Multiple studies have used the PAI approach to solve this issue 
but up to date, only two standard treatments have been compared. That is why Study 1 
compared CBT to an assimilative integration that combines CBT with exposure and emotion-
focused elements (CBT-EE). The most important predictors of treatment outcome in both 
conditions were identified and the question of whether model-determined treatment allocation 
using predictive information results in better treatment outcomes was addressed. 
2.1.2 Sample of Study 1 
 
 Study 1 used the data of an RCT that compared the efficacy of CBT to CBT-EE for 
patients with depression (Grosse Holtforth et al., 2019). The study was conducted in the 
psychotherapy outpatient clinic of the University of Zurich’s Department of Psychology. 
Participants had to meet the Diagnostic and Statistical Manual of Mental Disorders (American 
Psychiatric Association, 2000) criteria for MDD; be 18-65 years old and give informed 
consent. The following exclusion criteria were applicable: (1) current or lifetime psychotic 
disorder, (2) bipolar disorder (current or lifetime), (3) schizotypic, antisocial or borderline 
personality disorder, (4) current substance dependence, (5) acute suicidality, (6) being in 
psychological treatment for depression, and (7) health conditions that require medications that 
potentially exacerbate depression. Patients were randomized to receive 22 sessions of either 





confounding treatment effects with therapist effects. Of the 149 patients included, 72 were 
randomized to CBT and 77 to CBT-EE. Patient characteristics did not differ significantly in 
both treatment groups. The majority of patients was female (53.9% and 59.2%), single or 
married and the length of the current depressive episode was shorter than two years. The 
majority of patients did not have a comorbid anxiety disorder or personality disorder and did 
not take antidepressant medication.     
2.1.3 Data analytical strategy of Study 1 
 
 The primary outcome measure for Study 1 was the Beck Depression Inventory-II 
(BDI-II) (Hautzinger, Keller, & Kühner, 2006). Cronbach’s alpha was .88 in the current 
sample. 42 potential predictors were included in the analysis that can be classified into three 
categories: (1) sociodemographic variables, (2) depression related variables and (3) other 
baseline measures. Several of the other baseline measures target constructs that are 
particularly relevant to CBT-EE. The questionnaires that were used to measure them are the 
German version of the Ambivalence over the Expression of Emotion Scale (AVEX; Deighton 
& Traue, 2006), the German Questionnaire “Selbsteinschätzung Emotionaler Kompetenzen” 
(SEK-27; Berking & Znoj, 2008), the short German version of the Generalized Expectancies 
for Negative Mood Regulation Scale (NMR; Backenstrass, Pfeiffer, Schwarz, Catanzaro, & 
Mearns, 2008) and the subscales “mindfulness”, “over-identification”, “isolation”, “self-
kindness”, “self-judgment” and “common humanity” of the German version of the Self-
Compassion Scale (SCS; Hupfeld & Ruffieux, 2011). Furthermore, motive importance was 
measured with the Inventory of Approach and Avoidance Motives (IAAM; Grosse Holtforth 
& Grawe, 2000), the satisfaction of the motives with the Incongruence Questionnaire (INC; 
Grosse Holtforth & Grawe, 2003) and the cognitive and behavioral avoidance measured with 
the German version of the Cognitive-Behavioral Avoidance Scale (CBAS; Röthlin et al., 





comorbidities, the general symptomatology assessed with the SCL-K-9 (Klaghofer & Brähler, 
2001), basic dimensions of interpersonal problems (“love” and “dominance”) measured with 
the short version of the Inventory of Interpersonal Problems (IIP-32; Thomas, Brähler, & 
Strauß, 2011), dysfunctional attitudes measured by the subscales “recognition by others” and 
“performance evaluation” of the Dysfunctional Attitudes Scale (DAS; Hautzinger, Joormann, 
& Keller, 2005), rumination measured with the subscales “self-focused rumination” and 
“symptom focused rumination” of the German version of the Ruminative Response Scale-
short form (RRS; Kühner, Huffziger, & Nolen-Hoeksema, 2007), self-esteem assessed with 
the Rosenberg Self-Esteem Scale (RSES; Roth, Decker, Herzberg, & Brähler, 2008), strength 
of resources was measured with the Bernese Resource Inventory (RES; Trösken & Grawe, 
2002), perceived self-efficacy was assessed with the Self-Efficacy Scale (SWE; Jerusalem & 
Schwarzer, 1999), therapy expectations assessed by the subscales “hope for improvement” 
and “fear of change” of the Patient Questionnaire on Therapy Expectation and Evaluation 
(PATHEV; Schulte, 2005), and finally quality of life/well-being was measured with the 
WHO-QOL (World Health Organization, 1995) and the WHO-5 questionnaires (Brähler, 
Mühlan, Albani, & Schmidt, 2007) were used as well.  
 After removing missing baseline data with the R package missForest (Stekhoven, 
2013), the data set was split into two subsets, the CBT condition, and the CBT-EE condition. 
Then, BMA (Fragoso, Bertoli, & Louzada, 2018) was used for variable selection with 
treatment outcome as the dependent variable and to compute separate linear regression 
models for each treatment condition. Posterior probabilities were used to evaluate the relative 
importance of each potential predictor. Variables with a posterior probability over 0.5 are 
defined as important because they are included in over 50% of all the models. In total, 30,000 
linear regression models were estimated. For generating the PAI, regression models using a 





that each patient for whom the PAI prediction is estimated is excluded from the model to 
avoid overfitting. For each patient, a factual prediction (post-treatment BDI-II score of the 
treatment the patient has received) and a counterfactual prediction (post-treatment BDI-II 
score of the intervention the patient did not receive) were estimated. Finally, the observed 
change scores are compared. The PAI is the size of the predicted difference of receiving the 
treatment with the greater predicted benefit.  
2.1.4 Results of Study 1 
 
Variables predicting outcome in CBT-EE 
The most important predictors found in the CBT-EE condition were pre-treatment 
BDI-II score (Prob = 100%), age (Prob = 99.9%), comorbid axis-II disorder (Prob = 97.9%), 
being separated or divorced (Prob = 97.6), self-focused rumination (Prob = 97.3%), the SCL 
score (Prob = 96.6%), comorbid anxiety (Prob = 93.7%), hope for improvement (Prob = 
91.1%) and having accomplished an apprenticeship (Prob = 80.6%). A higher pre-treatment 
score, higher age, a comorbid axis-II disorder, being separated or divorced, higher self-
focused rumination, a higher SCL score, comorbid anxiety and having accomplished an 
apprenticeship predicted a higher post-treatment score. Higher hope for improvement 
predicted lower post-treatment scores. 
Variables predicting outcome in CBT 
Based on the posterior probabilities, the most important variables predicting treatment 
outcome in CBT were pre-treatment BDI-II score (Prob = 100%), recurrent depression (Prob 
= 83.3%), the number of previous depressive episodes (Prob = 81.1%), the subscale 
avoidance in the incongruence questionnaire (Prob = 67.6%) and gender (Prob = 50.8%). A 
higher pre-treatment score, recurrent depression, a higher number of episodes, higher 






The true error of the BDI-II post-treatment score predictions was 6.74. This stands for 
the average absolute difference between the predicted and actual scores across all patients. 
After treatment, patients who received their optimal treatment had a mean BDI-II score of 
8.65 (SD=7.49, n=62) whereas patients who were classified as having received their 
suboptimal treatment had a mean BDI-II score of 10 (SD=8.75, n=61). This results in an 
average PAI of 1.35 BDI-II points which can be read as follows: if patients had received their 
model-determined optimal treatment, their post-treatment BDI-II score would have been more 
than 1 point lower than if they had received the suboptimal treatment. For 46% of the patients 
the PAI was 5 or greater which means that for these patients, a substantial difference was 
predicted between the two treatments. This reference point was defined and used in prior 















2.1.5 Manuscript of Study 1 
 
Friedl, N., Berger, T., Krieger, T., Caspar, F., & Grosse Holtforth, M. (2019). Using 
the Personalized Advantage Index for individual treatment allocation to cognitive behavioral 
therapy (CBT) or a CBT with integrated exposure and emotion-focused elements (CBT-
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Even though different psychotherapeutic interventions for depression have shown to be 
effective, patients suffering from depression vary substantially in their treatment response. 
The goal of this study was to answer the following research questions: (1) What are the most 
important predictors determining optimal treatment allocation to cognitive behavioral therapy 
(CBT) or CBT with integrated exposure and emotion-focused elements (CBT-EE)?, and (2) 
Would model-determined treatment allocation using this predictive information result in 
better treatment outcomes? Bayesian Model Averaging (BMA) was applied to the data of a 
randomized controlled trial comparing the efficacy of CBT and CBT-EE in depressive 
outpatients. Predictions were made for every patient for both treatment conditions and an 
optimal versus a suboptimal treatment was identified in each case. An index comparing the 
two estimates, the Personalized Advantage Index (PAI), was calculated. Different predictors 
were found for both conditions. A PAI of 1.35 BDI-II points for the two conditions was found 
and 46% of the sample was predicted to have a clinically meaningful advantage in one of the 
therapies. Although the utility of the PAI approach must be further confirmed in prospective 
research, the present study study promotes the identification of specific interventions 
favorable for specific patients. 
Keywords: Personalized Advantage Index, treatment selection, depression, 
psychotherapy, CBT, precision medicine 
Clinical or Methodological Significance of this Article: Depression is a heterogenous 
disorder and patients differ based on numerous baseline characteristics. Some patients benefit 
more from one psychological treatment than from the other. As multiple treatments with 
empirically supported efficacy are available, it is difficult for clinicians as well as for patients 
to know which treatment to choose. Methodological advances could enable clinicians to make 





outcome. This study’s results show that by using BMA, it is possible to make treatment 
outcome predictions based on a limited set of baseline variables. The PAI findings show that 
for most patients it does not seem to play a major role if they receive standard CBT or a CBT 
treatment that assimilatively integrates exposure principles via emotion focused interventions 
(CBT-EE). However, for 46% of the sample, a substantial difference was predicted for the 
























Using the Personalized Advantage Index for individual treatment allocation to cognitive 
behavioral therapy (CBT) or a CBT with integrated exposure and emotion-focused 
elements (CBT-EE) 
By 2030, depression will be one of the leading causes of the global burden of disease 
(Mathers & Loncar, 2006). Nowadays, it is already one of the most common problems seen in 
clinical practice and is associated with great suffering of the affected patients as well as high 
societal costs (World Health Organization, 2008). Different effective psychotherapeutic 
approaches are available for the treatment of depression. Two of the most well-studied and 
frequently applied psychotherapies for major depressive disorder (MDD) are cognitive 
behavior therapy (CBT) and interpersonal psychotherapy (IPT) (Barth et al., 2016; Cuijpers et 
al., 2013; Lemmens et al., 2018). The question of whether all psychotherapies are equivalent 
has been addressed early on by Luborsky, Singer and Luborsky (1975) and a bit later by 
Stiles, Shapiro and Elliott (1986). They discuss the paradox of no differential effectiveness of 
different psychotherapies despite their technical diversity. Multiple meta-analyses suggest that 
the major psychotherapeutic approaches for depression do not differ with regard to their 
efficacy (Cuijpers & Dekker, 2005; Wampold, Minami, Baskin, & Tierney, 2002).  
However, whereas the average effects of different psychotherapeutic approaches do 
not differ on a group level, patients with depression vary substantially with regard to their 
individual treatment response and their individual illness course (Cuijpers et al., 2010). 
Increasing evidence suggests that patient characteristics and traits moderate the efficacy of 
different treatments at an individual level (Fournier et al., 2009), so that differential responses 
to treatments are not a scarcity (Simon & Perlis, 2010). Thus, by finding for each individual 
the psychological treatment that works best for him or her, it may be possible to improve the 





In this sense, the approach of precision medicine, which has a long tradition in 
medicine, tries to tailor medical treatments to the specific characteristics and needs of the 
patients (Deisenhofer et al., 2018; Hamburg & Collins, 2010). Accordingly, the use of 
prediction algorithms to improve and support clinical decision-making becomes increasingly 
common in the medical field. In clinical psychology and psychotherapy, the use of algorithms 
to predict the optimal treatment for an individual is growing as well (van Bronswijk et al., 
2018). One example is the “Personalized Advantage Index” approach which has the goal of 
identifying patients with a certain disorder (e.g., MDD) for whom one treatment works better 
than another (Cohen & DeRubeis, 2018). If there are two comparably effective treatments to 
choose from, the Personalized Advantage Index (PAI) identifies the treatment that predicts a 
better treatment outcome for a given patient with particular characteristics and provides a 
quantitative estimate of how much a particular treatment is better for this patient than another 
(DeRubeis et al., 2014). By this, the PAI approach promises to increase the likelihood of 
improving a patient’s mental health by identifying subsets of a given patient population who 
will likely show a certain response to a given treatment (Hollon et al., 2019). So far, its 
feasibility and relevance have been shown in several studies on the treatment of depression 
(Cohen et al., 2017; DeRubeis et al., 2005; Huibers et al., 2015). Huibers and colleagues 
(2015) for example, compared Cognitive Therapy (CT) with IPT and found that the patients 
randomized to their predicted optimal treatment (either CT or IPT) had an observed mean end 
score on the Beck Depression Inventory (BDI) of 11.8, while those who received their 
predicted non-optimal treatment had an end-BDI of 17.8. Similarly, Cohen and colleagues 
(2017) compared CBT with psychodynamic therapy (PDT) and found an average post-
treatment Hamilton Depression Rating Scale (HDRS) score of 1.6 points lower for the 





results indicate that being able to identify the best treatment for an individual with depression 
may make health care delivery more efficient (Hollon et al., 2019).  
So far, research on the PAI has focused on comparing standard manualized 
psychotherapeutic approaches, such as CBT with PDT. What has not been done so far is the 
comparison of a standard psychotherapy with a form of psychotherapy that integrates 
additional interventions into the standard approach following the principles of assimilative 
integration. Assimilative integration entails the systematic inclusion of techniques and 
attitudes of a supplementary therapy into a therapist’s primary therapeutic approach 
(Castonguay, Newman, Borkovec, grosse Holtforth, & Maramba, 2005; Messer, 1992). The 
difference to prior studies is that the treatments being compared are largely similar with the 
exception that the “new” treatment integrates additional interventions and principles that the 
standard treatment did not while preserving the overall therapeutic approach.  
In the current study, Exposure-Based Cognitive Therapy (EBCT-R; grosse Holtforth et 
al., 2012; Hayes, Beevers, Feldman, Laurenceau, & Perlman, 2005) is compared with 
standard CBT. EBCT-R integrates principles of exposure therapy operationalized via 
interventions from emotion-focused therapy (e. g., empty chair and two-chair interventions) 
into a cognitive-behavioral treatment in an attempt to increase a patient’s level of emotional 
processing. Emotional processing is seen as a key mechanism of change for the improvement 
in depression (Grosse Holtforth et al., 2019; Hayes, 2015; Pinheiro, Mendes, Silva, 
Gonçalves, & Salgado, 2018). Even though the application of exposure principles in 
depression treatment is fairly new, EBCT-R has been associated with significant reductions in 
depressive symptoms and has shown to be equally effective as CBT and produce effect sizes 
of similar size (grosse Holtforth et al., 2012; Grosse Holtforth et al., 2019; Hayes et al., 2005). 
At this point, it is important to note that the original trial (Grosse Holtforth et al., 2019) did 





additional elements into an existing approach according to the principles of assimilative 
integration. In order to stress both, the underlying standard approach (CBT) as well as the 
integrated elements (i. e., use of emotion-focused interventions as a way to realize exposure 
principles), we decided to use the abbreviation “CBT-EE” instead of the previously used 
“EBCT-R” for this integrative condition. Consequently, the design of the trial as well as the 
use of the PAI approach promise to improve treatment allocation by empirically identifying 
individual outcome predictors and providing a model for optimal treatment allocation. 
To reach this goal, the present study set out to answer the following research 
questions: (1) What are the most important predictors determining optimal treatment 
allocation to CBT or CBT-EE? and (2) Would model-determined treatment allocation using 
this predictive information result in better treatment outcomes? 
Method 
This study was based on a randomized controlled trial (RCT) comparing the efficacy 
of CBT and CBT-EE (Grosse Holtforth et al., 2019). The study was conducted at the 
outpatient clinic of the Department of Psychology at the University of Zurich. Each patient 
was randomized to receive 22 sessions of either CBT or CBT-EE. In order to reduce the risk 
of confounding treatment effects with therapist effects, therapists provided both treatments 
and were assigned an equal number of patients in both conditions. Therapists in the CBT 
condition were instructed to refrain from using emotion-focused interventions. Of the 149 
individuals that were included, 72 were randomized to CBT and 77 were randomized to CBT-
EE. Participants met the following inclusion criteria: (1) meeting Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR; American Psychiatric American Psychiatric 
Association, 2000) criteria for MDD, (2) being 18 to 65 years old and (3) giving informed 
consent. Details about the study design and a sample description are described elsewhere 






Primary outcome. The primary outcome measure for the present study was the Beck 
Depression Inventory-II (BDI-II; Hautzinger, Keller, & Kühner, 2006). The BDI-II is the 
most common used self-assessment questionnaire to evaluate the severity of depression. The 
reliability, validity and sensitivity to change of the German BDI-II has been shown to be 
satisfactory in prior studies (Kühner, Bürger, Keller, & Hautzinger, 2007). In the current 
sample, Cronbach’s alpha was .88. 
Predictor variables. Following an exploratory approach, a total of 42 potential 
predictors were included in the analysis. Various variables that had been measured at baseline 
were included as possible post-treatment predictors. To provide a better overview of the 
variables included in the analysis, they can be classified into three categories: (1) 
sociodemographic variables, (2) depression related variables and (3) other baseline variables. 
In the RCT, some of the other baseline variables had been chosen theoretically to assess 
constructs particularly relevant to CBT-EE. These variables are: ambivalence over the 
expression of emotion measured using the German version of the Ambivalence over the 
Expression of Emotion Scale (AVEX; Deighton & Traue, 2006), emotion regulation skills 
measured with the German questionnaire “Selbsteinschätzung Emotionaler Kompetenzen” 
(SEK-27; Berking & Znoj, 2008), negative mood regulation measured with the short German 
version of the Generalized Expectancies for Negative Mood Regulation Scale (NMR; 
Backenstrass, Pfeiffer, Schwarz, Catanzaro, & Mearns, 2008), as well as self-compassion 
measured using the subscales “mindfulness”, “over-identification”, isolation”, “self-
kindness”, “self-judgement” and “common humanity” of the German version of the Self-
Compassion Scale (SCS; Hupfeld & Ruffieux, 2011). For some of the other baseline 
variables, the assumed relevance to CBT-EE varied between the subscales, i.e., motive 





Holtforth & Grawe, 2000), satisfaction of motives measured with the Incongruence 
Questionnaire (INC; grosse Holtforth & Grawe, 2003), and the cognitive and behavioral 
avoidance measured with the German version of the Cognitive-Behavioral Avoidance Scale 
(CBAS; Röthlin et al., 2009). The remaining baseline variables were assumed to be similarly 
relevant to CBT and CBT-EE, i.e., comorbidities (anxiety, axis-I, axis-II), general 
symptomatology assessed by the SCL-K-9 (Klaghofer & Brähler, 2001), basic dimensions of 
interpersonal problems (“love” and “dominance”) assessed with the short version of the 
Inventory of Interpersonal Problems (IIP-32; Thomas, Brähler, & Strauß, 2011), as well as 
dysfunctional attitudes measured by the subscales “recognition by others” and “performance 
evaluation” of the Dysfunctional Attitudes Scale (DAS; Hautzinger, Joormann, & Keller, 
2005), rumination measured with the subscales “self-focused rumination” and “symptom 
focused rumination” of the German version of the Ruminative Response Scale-short form 
(RRS; Kühner, Huffziger, & Nolen-Hoeksema, 2007) self-esteem was measured using the 
Rosenberg Self-Esteem Scale (RSES; Roth, Decker, Herzberg, & Brähler, 2008), strength of 
resources measured with the Bernese Resource Inventory (RES; Trösken & Grawe, 2002), 
perceived self-efficacy measured with the Self-Efficacy Scale (SWE; Jerusalem & Schwarzer, 
1999), therapy expectations assessed by the subscales “hope for improvement” and “fear of 
change” of the Patient Questionnaire on Therapy Expectation and Evaluation (PATHEV; 
Schulte, 2005), as well as quality of life/well-being measured by the WHO-QOL (The World 
Health Organization quality of life assessment, 1995) and the WHO-5 questionnaires 
(Brähler, Mühlan, Albani, & Schmidt, 2007). 
Data analytical strategy 
Generally, we followed a bottom-up analytical approach with regard to predictor 
variables. This means that we treat the different types of predictors equally in the data 





Missing data and removing linear combinations. As in previous work using the 
PAI, we focused on those participants for which end of treatment BDI-II scores were 
available (DeRubeis et al., 2014a; Huibers et al., 2015). This leaves us with N = 123, 
representing 83% of the total sample. Distributed over the two conditions, there were 63 
patients in the CBT condition and 60 patients in the CBT-EE condition. Missing data in the 
baseline measures was imputed using the R package missForest (Stekhoven, 2013), which 
uses a random forest approach trained on the observed values of the data to predict missing 
values. Missing values were found in the variables: marital status, education, chronic 
depression, number of episodes, the WHO-5, AVEX, NMR and SCL. This method treats the 
missing value problem as a prediction problem (Tang & Ishwaran, 2017). The number of 
episodes had 13 missings (10.6%), marital status had 7 missings (5.7%), education, AVEX 
and NMR had four missings (3.3%) and chronic depression, WHO-5 and the SCL had two 
missings (1.6%). It is especially useful when dealing with mixed-type data, as is the case in 
the present study because it can handle categorical and continuous variables simultaneously 
(Stekhoven & Buhlmann, 2012). Because of its small imputation error, missForest has been 
shown to outperform other imputation methods and to be highly accurate (Waljee et al., 
2013). All further analyses are based on the imputed data set. The predictors included in the 
analyses were centered whereby continuous variables were centered at the grand mean and 
dichotomous variables were dummy coded to -0.5 and 0.5 (Kraemer & Blasey, 2004).  
Before building the regression model, we checked for linear combinations of features 
as an indication of redundancy because this may cause problems in linear regression. 
Although exact linear combinations are rare, they can occur if there is a larger number of 
features (Forte, 2015, pp. 27-28). We used the package caret because its findLinearCombos 
function can identify exact linear combinations of features (Kuhn, 2018). For the current data 





Bayesian Model Averaging (BMA). A standard data analysis approach to identify 
baseline variables that predict outcome in one treatment versus another would rely on one 
single model that can only include a limited number of potential predictors. A commonly used 
rule of thumb states that at least 10 observations per predictor are necessary to not exceed an 
acceptable level of bias (Peduzzi, Concato, Feinstein, & Holford, 1995; Vittinghoff & 
McCulloch, 2007). However, only a small number of predictors could have been included if 
we followed this approach. Furthermore, relying upon a single selected model may lead to 
overconfidence in the conclusions drawn regarding quantified associations. This might 
happen because the uncertainty in the model is ignored and because an alternative model with 
a different subset of predictors may fit the data equally well (Raftery, Madigan, & Hoeting, 
1997; Stock et al., 2014). The problem with overfitting is that the models might fail to 
replicate in future samples, thus creating considerable uncertainty about the scientific value of 
the findings (Babyak, 2004). A possible remedy for this dilemma that might provide a better 
predictive ability is to account for model uncertainty through Bayesian Model Averaging 
(BMA). The BMA method applies Bayesian inference for model selection and prediction 
resulting in less risky predictions and simpler model choice criteria (Fragoso, Bertoli, & 
Louzada, 2018). The Bayes factor is a way to investigate the evidence in favor of a null 
hypothesis, thus it is a method to quantify the evidence that supports a scientific theory (Kass 
& Raftery, 1995). BMA incorporates model uncertainty into the parameter estimates and 
inferences by estimating a posterior probability that each considered model is the correct one, 
given the data. Inferences can then be based on posterior means (weighted averages) of 
quantities across models (Raftery, 1995). To be precise, BMA averages over all possible sets 
of predictors and makes it possible to choose the most probable one. In summary, BMA is a 
way to derive sharper predictions from the data particularly in cases with many possible 





in several studies (Fernandez, Ley, & Steel, 2001a, 2001b; Ley & Steel, 2009; Steel, 2011; 
Stock et al., 2014).   
The data frame was split into two subsets, the CBT condition and the CBT-EE 
condition. Then, separate linear regression models were computed for each treatment 
condition (Deisenhofer et al., 2018) using the R package BAS (Clyde, 2018). We performed a 
Bayesian adaptive sampling (BAS) without replacement for variable selection in linear 
models using the function bas.lm with treatment outcome (BDI-II post-treatment score) as 
dependent variable. As mentioned before, posterior probabilities for each potential predictor 
are calculated and used to evaluate the relative importance of each variable. Posterior 
probabilities were also used as the criterion for evaluating the model performance. The 
following considerations determined choosing the appropriate bas.lm function: we used the 
"ZS-null" criterion for the priors, which is a Laplace approximation to the Jeffreys-Zellner-
Siow (JZS) prior for the integration of alpha = 1 only. The JZS prior uses the Jeffreys prior on 
sigma and the Zellner-Siow Cauchy prior on the coefficients. The optional parameter 'alpha' 
can be used to control the squared scale of the prior, where the default is alpha=1 (Clyde, 
2018). We decided to use "MCMC+BAS" method, which runs an initial Markov chain Monte 
Carlo (MCMC) algorithm to calculate marginal inclusion probabilities and then samples 
without replacement as in BAS. The combined option is recommended as it provides 
estimates with low bias compared to the sampling of BAS alone (Clyde, Ghosh, & Littman, 
2011). The number of models was set to 30,000 because it was assumed that each additional 
model will add only a small increment to the cumulative probability. This means that it leads 
to no nameworthy differences in posterior distributions. This assumption was later examined 
and analyzed. 
 Personalized Advantage Index (PAI). The first step in generating the PAI is to 





(DeRubeis et al., 2014; Efron & Gong, 1983). In this procedure, each target patient for whom 
the PAI prediction is estimated, is excluded from the model to avoid overfitting. For each of 
the 123 patients, two predictions were estimated: the post-treatment BDI-II score of the 
treatment the patient has received (factual prediction) and a post-treatment BDI-II score of the 
intervention the patient did not receive (counterfactual prediction). For the estimation of the 
factual prediction, the values of all the available pre-treatment variables, including their 
treatment assignment, were entered in the regression model. In the next step, using the 
predicted scores, we looked into the observed change scores of each patient which is the size 
of the predicted difference of receiving the treatment with the greater predicted benefit 
(optimal treatment) versus the non-optimal treatment. This provides us with a quantitative 
estimate, a predicted advantage, namely the PAI (DeRubeis et al., 2014). Higher absolute 
values of the PAI stand for stronger predicted benefits of one treatment over another. Up to 
today, PAI values vary from 1.6 on the Hamilton-Depression-Rating Scale (Cohen et al., 
2019) up to 8.9 on the BDI-II (Huibers et al., 2015).  
Results 
The importance of the potential predictors was evaluated based on their marginal 
posterior inclusion probabilities. Values above 0.5 indicate that the predictor has been 
included in more than half of the models, thus in over 15,000 models in the present case. In 
the following, we first report on the best five models for each treatment condition, and then 
we report the resulting PAI for the whole sample. 
Variables predicting outcome in CBT-EE  
The five best models predicting depression severity at post-treatment in the CBT-EE 
condition are shown in Table 1. For each model, the Bayes Factor, number of predictors, R2, 
log marginal likelihood and the posterior probabilities are provided. The first model (Model 





probability (0.03). Consequently, model 1 was selected as our final predictive model of post-
BDI-II score in the CBT-EE condition. 
Table 1
Five best models CBT-EE
Fit indices Model 1 Model 2 Model 3 Model 4 Model 5
Bayes Factor 1 0.9228315 0.6399822 0.4767033 0.4203144
Number of variables 13 12 12 12 14
R2 0.7767 0.7614 0.7578 0.7548 0.7823
log marginal likelihood 19.55932 19.4790081 19.1130018 18.8184556 18.6925643
Posterior probabilities 0.0335 0.0309 0.0215 0.016 0.0141  
 
While the selected model includes 13 variables in total, the strongest predictors of the 
post treatment BDI-II score in the CBT-EE condition included pre-treatment BDI-II score 
(Prob = 100%), age (Prob =  99.9%), comorbid axis-II disorder (Prob = 97.9%), being 
separated or divorced (Prob = 97.6%), self-focused rumination (Prob = 97.3%), the SCL score 
(Prob = 96.6%), comorbid anxiety (Prob = 93.7%), hope for improvement (Prob = 91.1%) and 
having accomplished an apprenticeship (Prob = 80.6%). A higher pre-treatment score, higher 
age, a comorbid axis-II disorder, being separated or divorced, higher self-focused rumination, 
a higher SCL score, comorbid anxiety and having accomplished an apprenticeship predicted a 
higher post-treatment score. Higher hope for improvement predicted lower pre-treatment 
scores. The effects of other variables appeared minimal due to their small posterior 
probabilities. See Table 2 for the posterior probabilities of the 13 variables included in the 
best model (Model 1). See Appendix 1 in the supplemental online material for the complete 







BMA results for the 13 variables included in the best model of the CBT-EE condition
Baseline variables Prob (%) Posterior mean (SD)
Sociodemographic variables
age 99.9 0.2818 (0.07252) 
separated/divorced 97.6 -7.627 (0.009889)
apprenticeship 80.6 -2.546 (1.857)
Depression related variables
pre-treatment BDI-II 100 -0.7006 (0.1160)
prior antidepressant trials 43.2 1.162 (1.785)
Other baseline measures
comorbid axis II 97.9 -5.180 (2.068) 
RRS (self-focused rumination) 97.3 -0.5317 (0.2229)
SCL-K-9 96.6 3.822 (1.674) 
comorbid anxiety 93.7 3.527 (2.217)
PATHEV (subscale hopfulness) 91.1 -1.936 (1.080)
DAS subscale performance evaluation 42.5 0.04713 (0.06966)
INC (avoidance) 23.6 0.4941 (1.206)




Variables predicting outcome in CBT 
Table 3 gives an overview of the five best models to predict treatment outcome for CBT. 
Based on the posterior probabilities and the Bayes Factor, Model 1 is the best model. For that 
reason, this model including six variables was selected as the final predictive model for the 
CBT condition. 
Table 3
Five best models for CBT
Fit indices Model 1 Model 2 Model 3 Model 4 Model 5
Bayes Factor 1 0.2965935 0.2451441 0.2366299 0.2267025
Number of variables 6 7 7 7 6
R2 0.5197 0.5253 0.5221 0.5215 0.4938
log marginal likelihood 11.7682 10.552804 10.3622878 10.3269389 10.2840802
Posterior probabilities 0.1125 0.0334 0.0276 0.0266 0.0255  
Note. BMA= Bayesian Model Averaging; RRS= Ruminative Response Scale; SCL-K-9= 
Symptom Checklist; PATHEV= Patient Questionnaire on Therapy Expectation and Evaluation; 






Based on the posterior probabilities, the most important predictors for treatment 
outcome in the CBT condition were pre-treatment BDI-II score (Prob = 100%), recurrent 
depression (Prob = 83.3%), the number of previous depressive episodes (Prob = 81.1%), the 
subscale avoidance in the incongruence questionnaire (Prob = 67.6%) and gender (Prob = 
50.8%). A higher pre-treatment score, recurrent depression, a higher number of episodes, 
higher avoidance and male gender predicted higher post-treatment scores. The WHO-QOL 
reached a posterior probability of 43.9%. The other baseline variables did not seem to 
contribute to the predictive ability of the model. See Table 4 for the posterior probabilities of 
the six variables included in the final prediction model. See Appendix 2 in the supplemental 
online material for the posterior probabilities of all variables measured at baseline. 
Table 4 
BMA results of the 6 variables included in the best model for CBT
Baseline variables Prob (%) Posterior mean (SD)
Sociodemographic variables
  gender 50.8  2.030 (2.524)
Depression related variables
  pre-treatment BDI-II 100  - 0.7702 (0.1444)  
  recurrent depression 83.3 7.868 (5.390) 
  depressive episodes 81.1  - 2.461 (1.816)
Other baseline measures
  INC (avoidance) 67.6  2.205 (2.128)
  WHO-QOL 43.9  - 1.266 (2.364)  
Note. BMA = Bayesian Model Averaging; INC= Incongruence Questionnaire; WHO-QOL = World 
Health Organisation Quality of Life Questionnaire. 
 
Figure 1 shows the cumulative probability for each of the models in the order they 
were sampled. It shows that, on the one hand, the cumulative probability is leveling off as 
each additional model adds only a small increment to the cumulative probability, i.e., that we 
would have gotten less and less information on the predictive ability of our models by running 
more models. On the other hand, with a smaller number of models we still gained a lot of 





of models approached 30,000 the cumulative probability did not increase very much anymore. 
Thus, it can be assumed that sampling more than 30,000 models would not lead to any 
nameworthy differences in posterior distributions and the additional information we would get 
would level off. 
 
Figure 1. Cumulative probabilities of the CBT model. 
Personalized Advantage Index 
Using the treatment specific predictors described above, the prediction of a patient’s 
post-treatment BDI-II score was computed separately for each treatment condition. The true 
error of the BDI-II post-treatment score predictions was 6.74, representing the average 
absolute difference between the predicted and actual, observed scores across all patients. The 
true error is to be distinguished from the PAI as it compares the observed outcome of the 
intervention that the patient received in the RCT with the prediction of the same intervention. 
Patients who were categorized as having received their optimal treatment had a mean BDI-II 





having received their suboptimal treatment had a mean BDI-II post-treatment score of 10 
(SD= 8.75, n= 61). Figure 2 shows the frequency of predicted BDI-II post-treatment scores 
for every patient in both the optimal and suboptimal treatment.  
 
Figure 2. Frequency histogram showing predicted post BDI scores for each patient in their 
optimal and their suboptimal treatment. 
 
First, an individual PAI was calculated for each patient. Then, an average PAI was 
calculated as the mean difference in BDI-II scores between the optimal and the suboptimal 
treatment for each patient, resulting in an average PAI of 1.35. This score can be read as 
follows: if patients had received their model-determined optimal treatment, their post-
treatment BDI-II score would have been more than 1 point lower than if they had received the 
non-optimal treatment. Figure 3 shows the frequencies of the individual PAIs. For 46% of the 





predicted between the two treatments. Hiroe and colleagues (2005) have found that a minimal 
clinically important difference corresponds to a 5-point difference in BDI-II scores. This 
reference point has been used in prior studies as well (Huibers et al., 2015).  
 
 
Figure 3. Frequency histogram showing PAI scores. 
 
Discussion 
The objectives of the present study were (1) to identify the most important predictors 
determining optimal treatment allocation to the integrative CBT-EE or standard CBT, and (2) 
to investigate if model-determined treatment allocation using this predictive information 
results in better treatment outcomes for an individual patient. With regard to predictors of 
treatment outcome in each of the interventions, different relevant predictors were identified 





or divorced, having accomplished a higher education than an apprenticeship, a lower pre-
treatment depressive symptomatology, no comorbid anxiety disorder, no comorbid axis-II 
disorder, a lower psychopathology, lower self-focused rumination, and more hope for 
improvement predict a better treatment outcome, i.e., a lower post-treatment BDI-II score. In 
contrast, in the CBT condition, a lower pre-treatment depressive symptomatology, female 
gender, fewer previous depressive episodes, no recurrent depression and a lower current 
incongruence regarding avoidance motives predicted a better treatment outcome.  
The distinction between prescriptive or prognostic outcome predictors offers an initial 
interpretation of our findings. Whereas prescriptive variables may support differential 
indication by predicting whether a patient will benefit more from one treatment in comparison 
to another, prognostic variable predict treatment outcome regardless of treatment condition. In 
the present study, the pre-treatment depressive symptomatology is the only prognostic 
predictor, i.e., the only variable that predicts treatment outcome in both conditions. This is in 
line with many previous studies that found the pre-treatment symptomatology to be a 
prognostic predictor, in the sense that higher pre-treatment severity is related to worse 
outcome in all treatment conditions (e.g., Cohen & DeRubeis, 2018; Dinga et al., 2018; van 
Bronswijk et al., 2018; DeRubeis et al., 2014;  Hamilton & Dobson, 2002). Interestingly, 
none of the baseline variables assumed to be relevant for CBT-EE due to their emotional 
focus such as emotion regulation skills, negative mood regulation, ambivalence over the 
expression of emotion, or self-compassion was empirically a relevant outcome predictor in 
this condition. At least two explanations may account for this finding. Either the therapists 
responded differentially to the emotional baseline characteristics patients displayed regardless 
of treatment condition and thereby prevented potential differential predictions 
(responsiveness; Stiles, Honos-Webb, & Surko, 1998), or the respective emotional pre-





how responsive therapists were. Thus, both treatment conditions would be able to deal well 
with different levels of emotional variables with no advantage of CBT-EE over CBT. As 
responsiveness may explain any absence of differential or prescriptive predictions, this 
explanation has to be kept in mind for explaining any absence of prescriptive predictions. 
Future process research focusing on responsiveness effects in this sample may help to 
distinguish the effects of responsiveness from non-specificity of predictors. 
Regarding further prescriptive predictors, our findings partly correspond to previously 
reported predictors of treatment outcome in CBT. For instance, female gender has been found 
to predict lower depressive symptomatology at post-treatment in both CBT and IPT (Huibers 
et al., 2015). Furthermore, previous depressive episodes and recurrent depression negatively 
predicted outcome in CBT (Blom et al., 2007; Thase, Reynolds, Frank, & Simons, 1994; 
Fournier et al., 2009). The difference between these previous findings and the results in our 
study is that in previous studies, female gender and chronicity of depression were prognostic 
predictors and thus relevant in various conditions. In the current study, these frequently found 
general predictors of outcome in depression treatments did not predict outcome in the CBT-
EE condition. Some of the variables identified as prescriptive predictors for CBT-EE in the 
current study, such as age, education level, and employment have been found to act as either 
prognostic or prescriptive predictors in CBT, CT or treatment with antidepressant medication 
(Chekroud et al., 2016; DeRubeis et al., 2014; Fournier et al., 2009; Huibers et al., 2015). 
Thus, it is rather surprising that we did not find these variables to predict outcome also in the 
CBT condition.  
Interestingly, self-focused rumination and hope for improvement were important 
predictors in the CBT-EE condition but not in the CBT condition. Apparently, ruminating too 
much about oneself decreases outcome specifically in CBT-EE. Particularly for patients 





emotion-focused interventions such as two-chair or empty-chair exercises, as a ruminative 
processing style regarding the self makes it even harder to change maladaptive self-
associations as it is intended in emotion-focused interventions (Greenberg, 2002). With regard 
to the lacking prediction in the CBT condition, this is in line with Huibers and colleagues 
(2015) who also assessed rumination with the RRS and did not find it to be an important 
predictor in CBT. A stronger hope for improvement may particularly facilitate process and 
outcome in CBT-EE, taking into account that emotion-focused interventions maybe 
particularly challenging and temporarily burdensome for the patient given the inherent 
activation of past negative emotions. Potentially, having more hope for improvement initially 
fosters patients’ motivation to “endure” burdensome emotions in service of better outcomes in 
the long run (Westermann, grosse Holtforth, & Michalak, in press).   
For the CBT condition, currently making less aversive experiences (lower avoidance 
incongruence) seems to be associated with better therapy outcomes, or put conversely, 
making stronger aversive experiences in life at intake decreases the chance for good therapy 
outcomes. This finding underscores the potential relevance of motivational factors, that have 
not been examined in earlier research, in the prediction of therapy outcome. 
Naturally, the above interpretations regarding prognostic and prescriptive predictors 
are somewhat speculative, so that further process research is necessary to test these 
interpretations empirically. In the end, we cannot rule out confounding factors and we cannot 
make any causal consumptions.  
The second goal of the current study was to investigate a model-determined treatment 
allocation and to calculate the PAI, a measure of the predicted advantage in one therapy 
compared to the other. Up to date, various forms of treatment have been compared using the 
PAI (e. g., Cohen et al., 2019; Huibers et al., 2015) but two forms of CBT (one that integrates 





have not been compared using the PAI yet. Growing empirical evidence supports the efficacy 
and feasibility of depression treatments that integrate principles of change from other 
orientations (Castonguay, Eubanks, Goldfried, Muran, & Lutz, 2015; Grosse Holtforth et al., 
2019). An advantage of treatments based on assimilative integration may be that therapists 
can stay within the theoretical framework that they are trained in but at the same time benefit 
from techniques of different approaches that potentially utilize other mechanisms of change 
(Lampropoulos, 2001). Another advantage of doing PAI research in the field of assimilative 
integration is that the same therapists can remain within his or her theoretical framework but 
conduct both of the compared interventions and does not have to be replaced depending on 
the predicted indication. In addition, the same-therapist design of the original study further 
facilitates the direct application the results of the PAI studies.  
This study’s results show that by using BMA, it is possible to make treatment outcome 
predictions based on a limited set of baseline variables. The present study set out to show that 
patients might benefit from different treatments despite sharing the same diagnosis. The 
current study found a PAI of 1.35, indicating that patients could have a post-treatment BDI-II 
score that is more than one point lower if they receive their model-determined optimal 
treatment in comparison to a treatment that is not optimal for them. This is a relatively small 
value compared to other studies that have found PAIs ranging from 1.6 (Cohen et al., 2019) 
up to 8.9 (Huibers et al., 2015). However, the smaller value could be explained by the fact 
that previous studies have compared treatments that differ more strongly from each other. In 
contrast, we have compared two treatments that have many commonalities due to their shared 
theoretical background in a CBT framework. Furthermore, the same therapists delivered both 
interventions which could also have lowered the PAI. Given the satisfactory adherence and 
equal allegiance for both conditions reported in the original study (grosse Holtforth et al., 





they receive standard CBT or a CBT treatment that assimilatively integrates exposure 
principles via emotion focused interventions (CBT-EE). Regardless of the rather small mean 
PAI, for 46% of the patients in this sample, a substantial difference was predicted between the 
two treatments as the PAI was 5 or greater. Other studies have found similar percentages 
ranging from 60% (DeRubeis et al., 2014) to 63% (Deisenhofer et al., 2018; Huibers et al., 
2015).  
The current study has several limitations. First, the sample size of the current study 
was relatively small. Due to this, it was not possible to build the models in one subsample and 
subsequently use another subsample for validation. However, the sample size requirements 
for an analysis like that could be lower if the assumptions about the underlying population 
parameters are outside the range of the reported study. Furthermore, studies with smaller 
samples are justified if they are designed to develop and validate prescriptive prediction 
scores to be tested further in future hypothesis-driven confirmatory studies (Luedtke et al., 
2019). Secondly, it is not known how the model would perform if applied to other populations 
that have baseline scores outside the range of this population since we do not have a second 
sample for validation. Future hypothesis-driven confirmatory studies are needed to validate 
the predictors found in the current study. Moreover, more data of RCTs that compare two 
different treatments should be made available for this kind of analyses. Particularly, studies 
that compare a standard treatment to an integrative treatment according to assimilative 
principles promise to have innovative potential in this context. Finally, another limitation is 
that therapist effects could not be analyzed in this study. It is known that therapist effects are a 
robust phenomenon, thus it is possible that they account for the different treatment outcomes 
in this sample (Johns, Barkham, Kellett, & Saxon, 2019; Wampold & Brown, 2005). The 
original RCT where the data was drawn from used the “same therapist design”. Even though 





remove them completely as allegiance might play a role and because there is not enough 
information about a potential carry-over effect due to the crossed-therapist design (Grosse 
Holtforth et al., 2019). Despite these limitations, the current study has the potential to make a 
significant contribution to the further understanding of depression treatment because it 
investigates implications for the use of an assimilative integration to CBT for patients with 
depression. Especially factors found to play a role in the treatment and change process of 
depression can be considered in clinical practice in order to provide the optimal treatment for 
each individual. Most importantly, the identified predictors need to be tested prospectively 
within clinical routine treatment settings in future research. Clinicians should take into 
account the important predictors found in this study and in previous studies to make an 
informed treatment recommendation for their patients. Furthermore, this study could help 
clinicians deciding whether to use their own therapeutic approach or whether it is necessary to 
include elements from another approach in the form of an assimilative integration. However, 
future studies with larger samples are necessary to validate the current findings. Moreover, 
prospective studies are needed in which a treatment selection model is integrated during the 
diagnostics process at the beginning of a psychotherapy in order to evaluate its added value.  
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Appendix 1   
BMA results based on the best 30000 models in the CBT-EE condition 
Baseline variables Prob (%) Posterior mean (SD) 
Sociodemographic variables   
age 99.9 0.2818 (0.07252)  
separated/divorced 97.6 -7.627 (0.009889) 
apprenticeship 80.6 -2.546 (1.857) 
gender  14.1 -0.06219 (0.6017) 
single 10.6 -0.09008 (0.009889) 
in a relationship/married 6.5 -0.1418 (0.009889) 
high school diploma 6.5 0.2333 (1.770) 
university diploma 4.6 0.002115 (0.4791) 
Depression related variables   
pre-treatment BDI-II  100 -0.7006 (0.1160) 
prior antidepressant trials 43.2 1.162 (1.785) 
depression severity 17.3 -0.07639 (0.5622) 
recurrent depression 7.5 0.02538 (0.5503) 
chronic depression 5.5 -0.01286 (0.3953) 
depressive episodes 4.8 0.009051 (0.1914) 
Other baseline measures   
comorbid axis 2 97.9 -5.180 (2.068)  
RRS (self-focused rumination) 97.3 -0.5317 (0.2229) 
SCL-K-9 96.6 3.822 (1.674)  
comorbid anxiety 93.7 3.527 (2.217) 
PATHEV (subscale hopfulness) 91.1 -1.936 (1.080) 
DAS subscale performance evaluation 42.5 0.04713 (0.06966) 
INC (avoidance) 23.6 0.4941 (1.206) 
PATHEV (subscale fear) 23.4 0.2480 (0.6715) 
IAAM (avoidance) 21.5 0.5539 (1.460) 
SCS (mindfulness) 17.6 -0.2564 (0.8262) 
comorbid axis 1 17.4 -0.4674 (1.614) 
NMR 17 -0.02505 (0.07659)  
IIP dominance 14.2 -0.1319 (0.5501) 
INC (approach) 11.9 0.1428 (0.6888) 
SCS (over-identification) 11.9 0.1303 (0.6431) 
WHO-5 11.5 0.1247 (0.5048) 
WHO-QOL 10.6 -0.2408 (1.082) 
IIP total score 10.3 0.1864 (0.8249) 
RRS (symptom focused rumination) 10 -0.01843 (0.09745) 
IAAM (approach) 9.5 0.00006262 (0.0007448)  
CBAS 9.4 0.1117 (0.6219) 
SCS (isolation) 9 0.04062 (0.4122) 
SWE 9 -0.05152 (0.5938) 
DAS subscale recognition by others 8.7 -0.001500 (0.03221) 
IIP love  8.6 0.04659 (0.4.117) 
SCS (self-kindness) 8.6 0.08874 (0.4961) 
SEK-27 7.4 -0.00382 (0.02165) 
RSES 6.9 0.01247 (0.4049) 
AVEX 5.9 -0.002390 (0.04782) 
SCS (self-judgment) 5 0.02540 (0.3322) 
SCS (common humanity) 3.8 0.01751 (0.2800) 






Appendix 2   
BMA results based on the best 30000 models in the CBT condition 
Baseline variables Prob (%) Posterior mean (SD) 
Sociodemographic variables   
gender  50.8  2.030 (2.524) 
age 10.5 -0.003545 (0.03373)  
university diploma 9.3 0.002596 (0.7654) 
in a relationship/married 8.7  0.06092 (0.1095) 
apprenticeship 7.3 0.1312 (0.8016) 
separated/divorced 6.6 -0.1349 (0.1095) 
single 5.7  0.02171 (0.1095) 
high school diploma 5.3 -0.06843 (1.525) 
Depression related variables   
pre-treatment BDI-II  100 -0.7702 (0.1444)   
recurrent depression 83.3 7.868 (5.390)  
depressive episodes 81.1 -2.461 (1.816) 
chronic depression 20.1 -0.2829 (1.220) 
prior antidepressant trials 10.1 0.09598 (1.032)  
depression severity 7.8 -0.05168 (0.5032) 
Other baseline measures   
INC (avoidance) 67.6  2.205 (2.128) 
WHO-QOL 43.9 -1.266 (2.364)  
comorbid anxiety 20.2 -0.7581 (2.030) 
CBAS 16.9 -0.1956 (0.9814) 
comorbid axis 2 14.8 0.2960 (1.119) 
RSES 14.1 -0.3169 (1.033) 
SCS (self-kindness) 13.3 -0.2281 (0.8699)  
PATHEV (subscale fear) 11.7 0.1301 (0.6904) 
RES 11 0.08776 (0.5777) 
NMR 10.2 0.007748 (0.05352) 
SCS (common humanity) 9.9 0.1382 (0.7022) 
DAS subscale performance evaluation 9.5 -0.006471 (0.03210) 
IIP total score 8.9 0.02489 (0.8316) 
SCS (isolation) 8.9 -0.1445 (0.7056) 
AVEX 8.8 -0.01103 (0.07968) 
SCS (over-identification) 8.7 0.06812 (0.5919) 
IIP love  8.6 0.1214 (0.6034) 
WHO-5 8.4 -0.03642 (0.5178) 
IIP dominance 7.8 -0.02376 (0.4832) 
SCL-K-9 7.5 0.09329 (0.7251) 
SCS (self-judgment) 7.4 0.05268 (0.5729) 
SWE 7.3 -0.1011 (0.8388) 
comorbid axis 1 7.1 0.03592 (1.258) 
RRS (symptom focused rumination) 6.5 0.003873 (0.09040) 
RRS (self-focused rumination) 6.5 -0.001968 (0.08079) 
SCS (mindfulness) 6.2 -0.02664 (0.4927)  
INC (approach) 5.9 0.03923 (0.7097) 
PATHEV (subscale hopfulness) 5.6 -0.03799 (0.5134) 
DAS subscale recognition by others 5.6 0.001.493 (0.03634) 
SEK-27 5.4 0.001799 (0.01931) 
IAAM (avoidance) 5.2 -0.04496 (0.6814) 





2.2 Study 2: Using the Personalized Advantage Index for individual treatment 
allocation to blended treatment or treatment as usual for depression in secondary 
care 
2.2.1 Goal of the study and research questions 
 
 Similar to Study 1, Study 2 uses the PAI approach for treatment selection for patients 
with depression. Blended treatment was compared to treatment as usual in secondary care in 
four European countries. Blended treatment is a new approach to treatment for depression that 
combines face-to-face therapies with internet-based elements. Research suggests the 
feasibility and efficacy of blended treatment and even though predictive modeling in e-mental 
health is still very young, machine learning techniques have been used in prior studies 
(Bremer et al., 2018). Study 2 had the goal to identify the important predictors of treatment 
outcome in both conditions and to investigate whether model-determined treatment allocation 
using predictive information results in better treatment outcomes. 
2.2.2 Sample of Study 2 
 
 The data for Study 2 was drawn from the European project “European COMPARative 
Effectiveness research on blended Depression treatment” (E-COMPARED) (Kleiboer et al., 
2016). This project investigated the clinical and cost-effectiveness of blended treatment 
compared to treatment as usual in routine care in nine European countries using a randomized 
controlled, non-inferiority trial. The current study used data from the Netherlands (N=83, 
33.9%), France (N=79, 32.2%), Switzerland (N=44, 18%) and Denmark (N=39, 15.9%) and 
has a total sample size of N=245. 68.2% of the participants were female and the mean age at 
baseline was 41.0 years (SD= 13.65). 33.5% were single, 31.8% were married and 12.8% 
were divorced. In the TAU condition, 57.9% of the sample suffered from a recurrent 





antidepressant medication at the time of the baseline measurement. In the blended treatment 
condition, 53.8% of the participants suffered from a recurrent depression, 61.3% had a 
comorbid anxiety disorder and half of the participants (49.6%) were taking antidepressant 
medication at baseline. 
 Patients who were randomized to blended treatment received individual face-to-face 
CBT with CBT-elements delivered through an internet-based treatment platform. The number 
of face-to-face sessions was reduced and replaced by online modules. The TAU treatment was 
defined as the treatment that patients with a diagnosis of depression receive in specialized 
mental health care, thus regular face-to-face CBT.  
2.2.3. Data analytical strategy of Study 2 
 
 The primary outcome measure was the Patient Health Questionnaire (PHQ-9; 
Kroenke, Spitzer, & Williams, 2001) assessed after 12 weeks. Cronbach’s alpha was .78. A 
total of 28 potential predictors that were measured at baseline have been included and can be 
classified into (1) sociodemographic variables, (2) symptomatology and quality of life, (3) 
healthcare utilization and (4) patient expectancy. Quality of life was measured with the EQ-
5D (EuroQol, 1990) and healthcare utilization was assessed with the TiC-P which is a self-
report questionnaire that examines healthcare consumption (Bouwmans et al., 2013). The 
Credibility and Expectancy Questionnaire (CEQ) was used to measure patient expectancy 
(Devilly & Borkovec, 2000).  
 After removing missing baseline data with the R package missForest (Stekhoven, 
2013), the data set was split into two subsets, the face-to-face condition and the blended 
treatment condition. Then, BMA (Fragoso et al., 2018) was used for variable selection with 
treatment outcome as the dependent variable and to compute separate linear regression 





importance of each potential predictor. Variables with a posterior probability over 0.5 are 
defined as important because they are included in over 50% of all the models. In total, 30,000 
linear regression models were estimated. For generating the PAI, regression models using a 
leave-one-out approach (Efron & Gong, 1983) were estimated for each patient. This means 
that each patient for whom the PAI prediction is estimated is excluded from the model to 
avoid overfitting. For each patient, a factual prediction (post-treatment PHQ-9 score of the 
treatment the patient has received) and a counterfactual prediction (post-treatment PHQ-9 
score of the intervention the patient did not receive) were estimated. Finally, the PAI results 
from the predicted difference of receiving the treatment with the greater predicted benefit.  
2.2.4. Results of Study 2 
 
Variables predicting outcome in TAU 
 The most important variables predicting the PHQ-9 score at 12 weeks in the TAU 
condition were the pre-treatment PHQ-9 score (Prob=100%), CEQ expectancy (Prob=97%), 
country of treatment Denmark (Prob=58%) and the following items from the TiC-P: “How 
many days did you use outpatient psychotherapeutic services in addition to psychotherapy?” 
(Prob=95%), “How many times did you consult a psychiatrist?” (Prob=64%) and “How many 
days did you attend a day-time treatment program in a psychiatric hospital?” (Prob=51%). A 
higher pre-treatment score, more consultations with a psychiatrist and more days in a day-
time treatment program in a psychiatric hospital prior to treatment predicted a higher PHQ-9 
score at 12 weeks. Higher expectancy scores, receiving TAU in Denmark, and more days 
using outpatient psychotherapeutic services in addition to the psychotherapy prior to treatment 







Variables predicting outcome in blended treatment 
 The most important predictors of PHQ-9 scores at 12 weeks in the blended treatment 
condition were pre-treatment PHQ-9 scores (Prob=99.9%), regular hospital admissions 
(Prob=99.9%), EQ-5D quality of life (Prob=74.6%), CEQ expectancy (Prob=72.3%), 
consulting self-help groups (Prob=70%) and being widowed (Prob=49.7%). A higher pre-
treatment PHQ-9 score, being widowed, more hospital admissions and consulting self-help 
groups predicted higher PHQ-9 scores at 12 weeks. A higher expectancy for improvement and 
a higher quality of life predicted lower PHQ-9 scores after 12 weeks. 
The PAI 
 The true error of the PHQ-9 predictions at 12 weeks was 4.16 which represents the 
difference between the predicted and actual scores across all patients. Patients who were 
categorized as having received their optimal treatment had a mean PHQ-9 score of 9.67 (n = 
124) at 12 weeks, whereas patients who were classified as having received their suboptimal 
treatment had a mean PHQ-9 score of 12.00 (n = 121). This results in an average PAI of 2.33 
points on the PHQ-9. Consequently, if patients had received their model-determined optimal 
treatment, their PHQ-9 score at 12 weeks would have been 2 points lower than if they had 










2.2.5 Manuscript of Study 2 
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Abstract: A variety of effective psychotherapies for depression are available but patients who 
suffer from depression vary in their treatment response. Combining face-to-face therapies with 
internet-based elements in the sense of blended treatment is a new approach to treatment for 
depression. The goal of this study was to answer the following research questions: (1) What are 
the most important predictors determining optimal treatment allocation to treatment as usual or 
blended treatment?, and (2) Would model-determined treatment allocation using this predictive 
information and the Personalized Advantage Index (PAI)-approach result in better treatment 
outcomes? Bayesian Model Averaging (BMA) was applied to the data of a randomized 
controlled trial comparing the efficacy of treatment as usual and blended treatment in depressive 
outpatients. Pre-treatment symptomatology and treatment expectancy predicted outcome 
irrespective of treatment condition, whereas different prescriptive predictors were found. A PAI 
of 2.33 PHQ-9 points was found, meaning that patients who would have received the treatment 
that is optimal for them would have had a post treatment PHQ-9 score that is two points lower 
than if they had received the treatment that is suboptimal for them. For 29% of the sample, the 
PAI was five or greater which means that a substantial difference between the two treatments 
was predicted. The use of the PAI approach for clinical practice must be further confirmed in 
prospective research, the current study supports the identification of specific interventions 
favorable for specific patients. 
Keywords: Personalized Advantage Index; depression; blended treatment; CBT; treatment 









Globally, 300 million people of all ages suffer from depression [1]. Depression is one of 
the most common problems seen in clinical practice and it is associated with high societal costs 
as well as great suffering [2]. Given this burden, the need for improved access to efficacious 
and cost-effective treatments is essential [3]. In the last decades, research has focused on 
examining different treatment options for depression. Especially cognitive behavior therapy 
(CBT) and interpersonal therapy (IPT) can be seen as first-line treatments [4, 5]. Moreover, 
current studies are aimed at scaling up treatment for depression. One way to do so is through 
internet-based therapies [5]. Whereas the most dominant format in which treatment is delivered 
is through face-to-face contact, internet-based therapies have received much attention in recent 
years [6]. The efficacy and cost-effectiveness of the latter have been supported by a growing 
number of research [7-9]. Even though only a few studies have directly compared internet-
based with face-to-face CBT for depression, results suggest it to have similar overall effects 
[6]. 
A newer approach to depression treatment is to combine web-based technologies with face-
to-face therapy, called blended treatment. Blended treatment includes any combination of face-
to-face therapy and internet-based interventions, e.g., web-based components are used as an 
adjunctive intervention or are integrated during face-to-face therapy [10]. Although research 
that investigates the efficacy of blended treatment formats is still scarce, preliminary results 
suggest their feasibility and their efficacy in reducing symptoms of depression [11-15]. For 
example, a randomized controlled trial by Berger and colleagues [16] showed the superiority 
of blended treatment, consisting of an internet-based intervention as an adjunct to face-to-face 
psychotherapy,  in comparison to regular face-to-face psychotherapy in a pragmatic randomized 
controlled study in patients with a unipolar affective disorder in routine care. Another recent 





depression and found blended treatment to be cost-effective [17]. Moreover, blended treatment 
has also been evaluated in an inpatient setting where patients suffering from depression that 
received an online self-help program in addition to inpatient psychotherapy improved 
significantly more than patients who received online information about depression in addition 
to inpatient psychotherapy [18]. Furthermore, a recent systematic review showed that compared 
to face-to-face therapy, blended treatment may help maintaining initially achieved changes 
within psychotherapy in the long-term [19].  
Potential benefits of blending treatments may be a greater reduction in depressive 
symptoms and increased cost-effectiveness [20] as well as an improvement of patients’ 
adherence to the treatment program [21]. Furthermore, an asset of blended treatment may be 
that it combines the advantages of both treatment forms [3, 14, 22, 23]. For example, the face-
to-face contact enables clinicians to individualize or tailor the treatment and to react in crisis 
situations, while providing online modules between sessions could promote patient engagement 
and enhance the translation of treatment into daily life (e.g., [24]). On the other hand, when 
online components are not used by the patients in blended treatments, reductions in the number 
of face-to-face sessions may lead to worse treatment outcomes [25]. Furthermore, therapists 
may raise concerns of overburdening depressed patients [18]. So far it is not clear, for which 
patients blended treatment may be a feasible option and for which patients a conventional 
treatment should be favored. 
Patients with depression may differ substantially from each other and evidence suggests 
that the diagnostic categories leave room for great diversity [26, 27]. This results in differences 
with regard to patients’ illness course and individual treatment response [28]. Research suggests 
that individual patient characteristics may moderate the efficacy of different treatments at an 
individual level [29]. It is, therefore, important to recognize that no single treatment is likely to 





from depression [26, 30]. This is why more and more researchers move away from investigating 
treatment efficacy on a group level and instead focus on custom-tailoring the treatment to the 
individual patient [30, 31]. In this sense, it may be a solution to increase the overall treatment 
response rates [32].  
Precision medicine tries to tailor treatments to the specific needs of the patient [33]. More 
recently, in clinical psychology and psychotherapy, algorithms are used that predict from which 
treatment a patient benefits the most [34]. As an example, Becker and colleagues [35] introduce 
a conceptual framework that helps classifying applications of predictive modeling in mental 
health research. These authors try to bridge the gap between psychologists and predictive 
modelers with providing a common language for classifying predictive modeling mental health 
research. They suggest that e-mental health researchers should focus more on the validity of 
model predictions instead of solely focusing on identifying predictors. Another example is the 
Personalized Advantage Index approach, which identifies patients with a certain disorder (e.g., 
major depression) who benefit more from one treatment than another [30]. Using the 
Personalized Advantage Index (PAI), it is possible to identify the treatment that predicts a better 
treatment outcome for a given patient if there are two comparably effective treatments to choose 
from [36]. The PAI estimates how much a specific treatment is better for an individual patient 
than another, and its feasibility and relevance have been shown in several studies on the 
treatment of depression [36-40]. Baseline patient characteristics can be can be divided into two 
types of predictors: A prognostic variable predicts treatment outcome irrespective of treatment 
condition whereas a prescriptive variable predicts a differential treatment response to two or 
more treatment modalities [29, 30]. Up to today, different treatments have been compared using 
the PAI and its values range from 1.4 when comparing CBT to CBT with integrated exposure 
and emotion-focused elements [38] up to 8.9 when comparing Cognitive Therapy to IPT [40]. 





another. Being able to identify the best treatment for an individual with depression is essential 
because it may make health care delivery more efficient [32]. Even though predictive modeling 
is still very young in the field of e-mental health [41], Bremer and colleagues [42] were able to 
predict clinical outcomes and costs of patients with depression prior to starting blended 
psychotherapy in a subsample of the current study using machine learning techniques. 
In the current study, treatment as usual (TAU), i.e., regular face-to-face psychotherapy, 
was compared to blended treatment for patients with major depressive disorder (MDD) in 
secondary care. The present study was set out to answer the following research questions: (1) 
What are the most important predictors determining optimal treatment allocation to TAU or 
blended treatment?, and (2) Would model-determined treatment allocation using this predictive 
information and the PAI-approach result in better treatment outcomes? To the best of our 
knowledge, this is the first study comparing different treatment delivering formats, i.e., 
traditional face-to-face CBT versus blended CBT, by using the PAI-approach.  
2. Materials and Methods 
Data used in the present study was drawn from the European project “European 
COMPARative Effectiveness research on blended Depression treatment” (E-COMPARED, 
February 2018) [43]. The E-COMPARED project included a randomized controlled, 
noninferiority trial that examined the clinical and cost-effectiveness of blended treatment 
compared to treatment as usual in routine care in nine European countries. Adult patients 
diagnosed with MDD were recruited in primary or in specialized mental health care. The current 
study uses the data of the four countries that recruited patients in specialized mental health care 
(France, the Netherlands, Switzerland and Denmark). Following inclusion criteria were met by 
participants: (1) being 18 years of age or older, (2) meeting Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV) diagnostic criteria for MDD as confirmed by a telephone-





minimal to severe symptoms of depression based on a score of 5 or above on the Patient Health 
Questionnaire-9 (PHQ-9) [45]. Exclusion criteria for participating in the study were: (1) high 
risk for suicide according to the M.I.N.I., (2) psychiatric comorbidity such as substance 
dependence, bipolar affective disorder, psychotic illness, obsessive compulsive disorder, (3) 
currently receiving another psychological treatment for depression, (4) being unable to 
comprehend the spoken and written language of the country where the study is conducted, (5) 
not having access to a computer with fast Internet connection and (6) not having a smartphone 
that is compatible with the mobile component of the intervention that is offered. Patients were 
randomized to blended treatment or TAU using an allocation scheme with a computerized 
random number generator at an allocation ratio of 1:1 and between 8 and 14 allocations per 
block. Details about the study design are described elsewhere [43]. For Switzerland, this study 
was approved by the cantonal ethics committees Bern and Zurich (registration number: 001/15; 
date 18/03/2015), for Denmark, the study was approved by the Ethics Committee of the Region 
of Southern Denmark (registration number S-20150150; date 18/11/2015), for France, the study 
was approved by the “Comité de protection des personnes”, Ile de France V (registration 
number 15033-n° 2015-A00565-44; date 2/06/2015) and for the Netherlands, the study was 
approved by METC VUMC (registration number 2015.078; date 8/05/2015. Furthermore, all 
participants provided written informed consent and gave permission to all E-COMPARED 
partners to use their anonymized data. 
2.1. Sample  
The current study has a sample size of N = 251. The sample consists of 83 participants from 
the Netherlands (33.9%), 79 participants from France (32.2%), 44 from Switzerland (18.0%), 
and 39 participants from Denmark (15.9%). The mean age at baseline was 41.0 years (SD = 
13.7) and 68.2% of the participants were female. The majority were either single (33.5%) or 





the TAU condition, 57.9% of the sample suffered from a recurrent depression, 45.2% from a 
current melancholic depressive episode, 7.9% from a comorbid dysthymia and 46.8% from a 
comorbid anxiety disorder. 53.2% of the patients are taking antidepressant medication at the 
time of the baseline measurement. In the blended treatment condition, 53.8% of the participants 
suffered from a recurrent depression, 34.5% from a current melancholic depressive episode, 
5.9% from a comorbid dysthymia and 61.3% had a comorbid anxiety disorder. Half of the 
participants (49.6%) were taking antidepressant medication at baseline. 
2.2. Interventions 
 Individual face-to-face CBT was combined with internet-based CBT-elements delivered 
through a platform for blended treatment. Three different online platforms were used across the 
participating countries. Switzerland used “Deprexis” [46], whereas Denmark used NoDep [47] 
and France and the Netherlands used the platform “Moodbuster” [3]. The most important 
components of the treatment were cognitive restructuring, behavioral activation, 
psychoeducation, and relapse prevention that were delivered over 11-20 sessions. In the blended 
treatment, a smaller number of face-to-face sessions is offered and some sessions are replaced 
by online modules. Treatment was provided by CBT therapists who received special training 
on how to deliver blended treatment. In Switzerland and the Netherlands, the therapists were 
either licensed CBT therapists or CBT therapists who were supervised by an experienced 
licensed CBT therapist. In Denmark, the treatment was delivered by either licensed 
psychologists or psychologist under supervision of licensed psychologists. In France, blended 
treatment was provided by licensed psychotherapists [43]. 
The TAU treatment was defined as the routine care that patients received in specialized 
mental health care when they are diagnosed with depression. In practice, this meant that the 





2.3. Measures  
2.3.1. Primary outcome 
 The primary outcome measure for this study was the PHQ-9 [45] assessed after 12 
weeks. The PHQ-9 consists of nine questions which are based upon the DSM-IV criteria for 
the diagnosis of depressive disorders. It is used as a diagnostic instrument and as a severity 
measure for depression. A 5-point difference in PHQ-9 scores is seen as clinically significant 
[48]. The validity and sensitivity to change of the PHQ-9 were satisfactory in previous studies 
[49] [50]. Cronbach’s alpha in the present study was .78. 
2.3.2. Predictor variables 
 We used an exploratory approach and included a total of 28 potential predictors 
measured at baseline in the analysis. All variables of the baseline assessment that did not exceed 
a number of acceptable missing values (< 50%) were included. We classified the variables into 
four categories: (1) sociodemographic variables, (2) symptomatology and quality of life, (3) 
healthcare utilization and (4) patient expectancy.  
 The sociodemographic variables included age, marital status, education, gender and 
country and were assessed with single item questions. Variables related to symptomatology and 
treatment history were recurrent depression, therapy preference, dysthymia, melancholic 
depressive episodes, comorbid anxiety, and current use of antidepressants. Quality of life was 
measured with the EQ-5D [51]. Healthcare utilization was assessed with the TiC-P [52]. The 
TiC-P examines healthcare consumption and productivity losses as a consequence of a mental 
disorder via a self-report questionnaire. The questions include contacts within the healthcare 
sector and the use of medication. All the questions aim at the period of the last four months 





Patient expectancy was measured by the Credibility and Expectancy Questionnaire (CEQ; 
[53]). 
Table 1  
TiC-P items included in the analysis 
“How many times did you consult a 
general practitioner?”,  
“How many times did you consult a 
psychologist?”,  
“How many times did you consult a 
psychotherapist?”, “How many times 
did you consult a psychiatrist?”, 
“How many times did you consult a 
professional from an ambulatory 
mental health institution?”,  
“How many times did you consult a 
professional from a clinic for alcohol 
or drugs?”, “How many times did you 
consult self-help groups?” 
“How many days did you spend in a 
day-time treatment program in a 
regular hospital?”,  
“How many days did you spend in a 
day-time treatment program in a 
psychiatric hospital?”, “How many 
days did you use outpatient 
psychotherapeutic services in 
addition to your psychotherapy?” 
“How many admissions 
to a regular hospital did 
you have?”, “How many 
admissions to a 
psychiatric hospital did 
you have?”, 
“How many admissions 
to a rehabilitation clinic 
did you have?”,  
“Do you have a paid 
job?”,  
“Did health problems 
oblige you to call in sick 





2.4. Data analytical strategy 
Regarding the predictor variables, a bottom-up approach was followed which means that 
even though some variables might have a particular relevance to one treatment or the other, the 
predictors are treated equally in the data analysis.  
2.4.1. Missing data  
In line with previous research using the PAI approach, we included those participants for 
which PHQ-9 scores after 12 weeks were available [36, 38, 40]. This left us with N = 245, 
representing 97.6% of the total sample. Distributed over the two conditions, there were 126 
patients in the TAU condition and 119 patients in the blended treatment condition. With regard 
to the baseline measures, missing values were found in the dimensions credibility and 
expectancy of the CEQ (3.7% resp. 4.1%), the EQ-5D (1.6%), antidepressants (1.2%), prior 
psychotherapy (40.4%), comorbid melancholic episodes (14.3%), comorbid dysthymia (5.3%), 
comorbid anxiety (2.4%), and some items of the TiC-P (2.0-40.8%). We imputed missings in 
the baseline measures with the R missForest [54]. Here missing values are predicted on the 
basis of a random forest approach, trained on observed values of the available data. An 
advantage of missForest is that it imputes categorical and continuous variables simultaneously 
[55]. It has been shown to be highly accurate and to outperform other imputation methods due 
to its small imputation error [56]. The imputed data set is the basis for all analyses that follow.  
2.4.2. Bayesian Model Averaging (BMA) 
There are different data analysis approaches that can be used to identify baseline variables 
that predict outcome in one treatment versus another. Data analysis approaches that rely on one 
model only, can only include a limited number of baseline measures that could be predictors. 
In that case, the most common rule that is used states that at least 10 observations per predictor 





approach, we could have only included a small number of predictors. Furthermore, the problem 
with relying upon a single selected model is that it may result in overconfidence in the 
conclusions drawn regarding quantified associations. The problem is that there may be 
alternative models that have different subsets of predictors that fit the data just as well as the 
one selected model [59, 60]. Overfitted models cause uncertainty regarding  the actual value of 
findings because they may not replicate in future samples [61]. Bayesian Model Averaging 
(BMA) is a method that can account for model uncertainty while providing a better predictive 
ability. The BMA method has two advantages. First, it results in predictions that are less risky 
and second, BMA provides simpler model choice criteria because it uses Bayesian inference 
for model prediction and selection [62]. With BMA, a posterior probability is estimated on the 
basis that each considered model is the correct one. This included the aforementioned model 
uncertainty in the estimates for the parameter and inferences. That means that BMA averages 
over all possible predictor sets and delivers model choice criteria that help to identify the most 
probable model. With using BMA, sharper predictions can be derived from the data, especially 
in cases with many possible predictors but a limited sample size. Several studies have supported 
BMA’s predictive performance [60, 63-66].   
The data frame was devided into two subsets, the TAU condition, and the blended treatment 
condition. Using the R package BAS, for each condition, a separate linear regression model was 
computed [67]. Then Bayesian adaptive sampling (BAS) without replacement for variable 
selection in linear models using the function bas.lm with treatment outcome was applied (PHQ-
9 score after 12 weeks) as the dependent variable. The relative importance of each variable is 
evaluated using the posterior probabilities that are calculated for each potential predictor. The 
marginal posterior inclusion probabilities function as the criteria for determining the importance 
of the potential predictors. Values above 0.5 point out that the predictor has been incorporated 





variables are split into their different categories, which enables a precise interpretation of the 
results. The model performance was further evaluated using posterior probabilities. The 
appropriate bas.lm function was chosen based on the following considerations: a Laplace 
approximation to the Jeffreys-Zellner-Siow (JZS) prior for the integration of alpha = 1 was used 
as the criterion for the priors which is called the "ZS-null". The JZS prior uses the Zellner-Siow 
Cauchy prior on the coefficients and the Jeffreys prior on sigma. The squared scale of the prior, 
where the default is alpha=1 can be controlled using the optional parameter 'alpha' [38, 67]. 
Marginal inclusion probabilities were calculated with the "MCMC+BAS" method, which runs 
an initial Markov chain Monte Carlo (MCMC) algorithm and then samples without replacement 
as in BAS. Compared to the BAS alone, the “MCMC+BAS” method is the preferred option 
because it provides estimates with low bias [68]. The number of models was set to 30,000 
assuming that each additional model would add only a small increment to the cumulative 
probability, i.e., not leading to essential differences in posterior distributions. Due to the limited 
sample size, the models have been built and tested in the same data set.  
2.4.3. Personalized Advantage Index (PAI) 
When predicting the therapy outcome for each patient, applying a leave-one-out approach 
(“jackknife”) to estimate regression models is an essential beginning step in generating the PAI 
[36, 38, 69]. In this procedure, overfitting can be avoided by excluding each target patient for 
whom the PAI prediction is estimated from the model. For each patient, two regression models 
were built using the treatment specific predictors identified with BMA. For each patient, a 
factual prediction (PHQ-9 score at 12 weeks of the treatment the patient has received) and a 
counterfactual prediction (PHQ-9 score at 12 weeks of the intervention the patient did not 
receive) were estimated. In the next step, those two predictions were compared and the 
prediction that resulted in the best outcome for the patient was defined to be the optimal 





difference of receiving the treatment with the greater predicted benefit is ultimately the PAI 
[36]. The higher the absolute values of the PAI, the stronger is the predicted benefit of one 
treatment over another. The interpretation of the PAI can be demonstrated with a recent study 
that used the PHQ-9 as primary outcome and found a PAI of 2.5 [70]. This means that if patients 
had received their “optimal” treatment (out of the two), their PHQ-9 score at 12 weeks would 
have been 2.5 points lower than if they had obtained their non-optimal treatment.  
3. Results 
Henceforth, we firstly report the five best models for each treatment condition, and 
secondly, we report the PAI results. The best models are defined based on the highest posterior 
probability and the lowest BIC.   
3.1. Variables predicting outcome in TAU 
The five best models predicting depression severity at 12 weeks in the TAU condition are 
displayed in Table 2. The Bayes Factor, number of predictors, R2, log marginal likelihood, and 
the posterior probabilities are provided for each model. Model 1 has the largest Bayes Factor 
and the largest posterior probability (0.02) and thus seems to fit the data best. As a result, Model 





Five best models TAU 
     
Fit indices Model 1 Model 2 Model 3 Model 4 Model 5 
Bayes Factor 1 0.934 0.597 0.572 0.510 
Number of variables 6 6 6 5 6 
R2 0.428 0.445 0.441 0.440 0.439 
log marginal likelihood 22.729 22.659 22.213 22.170 22.056 





While the selected model includes six variables in total, the strongest predictors of the 
PHQ-9 score at 12 weeks in the TAU condition included pre-treatment PHQ-9 score 
(Prob=100%), CEQ expectancy (Prob=97%), “How many days did you use outpatient 
psychotherapeutic services in addition to your psychotherapy?”, (Prob=95%), “How many 
times did you consult a psychiatrist?” (Prob=64%), Denmark (Prob=58%) and “How many 
days did you attend a day-time treatment program in a psychiatric hospital?” (Prob=51%). A 
higher pre-treatment score, more consultations with a psychiatrist and more days in a day-time 
treatment program in a psychiatric hospital prior to treatment predicted a higher PHQ-9 score 
at 12 weeks. Higher expectancy scores, receiving TAU in Denmark, and more days using 
outpatient psychotherapeutic services in addition to the psychotherapy prior to treatment 
predicted lower PHQ-9 scores at 12 weeks. The effects of other variables appeared minimal 
due to their small posterior probabilities. See Appendix 1 in the supplemental online material 
for the complete list of variables and their inclusion probabilities.  
3.2. Variables predicting outcome in the blended treatment 
Table 3 gives an overview of the five best models to predict treatment outcome in the 
blended treatment condition. Based on the posterior probabilities and the Bayes Factor, Model 
1 was rated the best model. Thus, Model 1 was selected as the final predictive model for the 












Five best models blended treatment 
     
Fit indices Model 1 Model 2 Model 3 Model 4 Model 5 
Bayes Factor 1 0.887 0.577 0.525 0.516 
Number of variables 6 5 4 6 6 
R2 0.398 0.416 0.392 0.429 0.446 
log marginal likelihood 19.852 19.731 19.301 19.207 19.190 
Posterior probabilities 0.012 0.011 0.007 0.006 0.006 
 
Based on the posterior probabilities, the most important predictors for treatment outcome 
in blended treatment were pre-treatment PHQ-9 score (Prob=99.9%), regular hospital 
admissions (Prob=99.9%), EQ-5D quality of life (Prob=74.6%), CEQ expectancy 
(Prob=72.3%), consulting self-help groups (Prob=70.0%) and being widowed (Prob= 49.7%). 
CEQ credibility reached a posterior probability of 42.9%. A higher pre-treatment PHQ-9 score, 
being widowed, more hospital admissions and consulting self-help groups predicted higher 
PHQ-9 scores at 12 weeks. A higher expectancy for improvement and a higher quality of life 
predicted lower PHQ-9 scores after 12 weeks. See Appendix 2 in the supplemental online 
material for the posterior probabilities of all variables measured at baseline.  
3.3. Personalized Advantage Index 
Using the treatment specific predictors described above, the prediction of a patient’s PHQ-
9 score after 12 weeks was computed separately for each treatment condition. The true error of 
the PHQ-9 score predictions at 12 weeks was 4.16, representing the average absolute difference 
between the predicted and actual, observed scores across all patients. Patients who were 
categorized as having received their optimal treatment had a mean PHQ-9 score of 9.67 (n = 





treatment had a mean PHQ-9 score of 12.00 (n = 121). Figure 1 shows the frequency of 
predicted PHQ-9 scores at 12 weeks for every patient in both the optimal and suboptimal 
treatment.  
 
Figure 1. Frequency of predicted PHQ-9 scores at 12 weeks. 
In the first step, an individual PAI was calculated for each patient. Secondly, the average 
PAI was calculated as the mean difference in PHQ-9 scores between the optimal and the 
suboptimal treatment for each patient. The average PAI of the current study is 2.33. The PAI 
can be read as follows: if patients had received the treatment that is “optimal” for them, their 
PHQ-9 score at 12 weeks would have been 2.33 points lower than if they had received the 
treatment that is suboptimal for them. In Figure 2, the frequencies of the individual PAIs are 
shown. A PAI that is five or greater would mean that a substantial difference was predicted 
between the two treatments because 5 points on the PHQ-9 stand for a minimal clinically 
meaningful difference for individual change [71]. This was the case for 29% of the patients in 






Figure 2. Frequencies of individual PAIs. 
4. Discussion  
Regarding the predictors of treatment outcome at 12 weeks in each of the interventions, 
different relevant predictors were identified for TAU and blended treatment, respectively. In 
the TAU condition, a lower pre-treatment PHQ-9 score, less consultations with a psychiatrist, 
and less days in a day-time treatment program in a psychiatric hospital, higher expectancy, 
receiving TAU in Denmark, and more days using outpatient psychotherapeutic services in the 
four months prior to the study predicted a better treatment outcome, i.e., a lower PHQ-9 score 
(at 12 weeks). In contrast, in the blended treatment condition, a lower pre-treatment PHQ-9 
score, not being widowed, less hospital admissions and consulting self-help, a higher 
expectancy for improvement and a higher EQ-5D score predicted lower scores at 12 weeks, 
thus a better treatment outcome.  
To offer an initial interpretation of our findings, the distinction between prescriptive and 
prognostic predictors is used. Prognostic variables predict treatment outcome regardless of 
treatment condition [30, 38]. In contrast, prescriptive variables may support differential 





to another. In the present study, the pre-treatment depressive symptomatology and treatment 
expectancy are the only prognostic predictors, i.e., the only variables that predict treatment 
outcome in both conditions. This is in line with previous research that has found pre-treatment 
symptomatology and expectancy to be important predictors of treatment outcome, in the sense 
that higher symptomatology before treatment predicts worse end-state symptomatology [30, 34, 
36, 38, 72, 73] and higher expectancy for improvement predicts better treatment outcome [74, 
75]. Interestingly, for internet-based treatments, higher baseline symptomatology is not 
necessarily a negative predictor of treatment outcome. More often the opposite is found, i.e. 
that higher depressive symptomatology pre-treatment predicts better treatment outcome [76-
78]. This might be partly explained by the efficacy nature of previous RCTs in comparison to 
the routine care and effectiveness nature of the current study.  
Regarding the prescriptive predictors, our findings partly corroborate findings from 
previous studies predicting treatment outcome for patients with depression. With regard to 
prescriptive predictors of the blended treatment condition, a lower quality of life, being 
widowed predicted worse treatment outcome. In contrast to the present result, the study by 
Huibers and colleagues [40] found higher quality of life to be a prognostic predictor, i.e., to 
predict favorable outcome irrespective of treatment condition.  
For the TAU condition, more consultations with a psychiatrist, and more days in a day-
time treatment program in a psychiatric hospital predicted worse treatment outcome. This could 
mean that patients’ symptomatology and patients’ general functioning is too severe to be able 
to profit from TAU. Furthermore, to our knowledge, there are no international studies regarding 
psychotherapy of depression indicating country as a relevant predictor of outcome.  
Healthcare utilization within the four months prior starting treatment was found to be a 
prescriptive predictor in both conditions. Healthcare uptake may be a proxy for a higher somatic 





previous studies, more complex cases (e.g., with chronic symptoms and psychiatric 
comorbidities) or more severe depressive symptomatology predicted a worse therapy outcome 
[29, 38, 79-81]. Interestingly, more hospital admissions only predicted worse treatment 
outcome in the blended treatment condition. A possible interpretation of this finding is the fact 
that the online modules in the blended treatment protocol are highly standardized to target 
depressive symptomatology. As a result, they may have not sufficiently addressed comorbid 
symptoms. Somatic comorbidities in patients with depression are not a scarcity and have an 
influence on individual treatment response and illness course because they can complicate 
treatment [81]. Furthermore, number of hospital admissions may also be a proxy for case 
complexity and higher mental burden which in turn may have a negative impact on treatment 
outcome.  
This study’s results demonstrate that BMA makes it possible to use a limited set of baseline 
variables to predict treatment outcome. This is in line with a recent study by Bremer and 
colleagues [42] that showed the feasibility of providing personalized treatment 
recommendations at baseline regarding clinical and cost-effectiveness using a subsample of the 
current study by evaluating various machine learning techniques. Moreover, the present study 
showed that despite sharing the same diagnosis, patients might benefit more from different 
treatments. The current study found a PAI of 2.33, indicating that patients could have a PHQ-9 
score at 12 weeks that is on average more than two points lower if they receive their model-
determined optimal treatment in comparison to the suboptimal treatment. This value is in the 
range of other studies that have found PAIs ranging from 1.35 [38] up to 8.9 [40]. Importantly, 
for almost one third (29%) of the patients in the present study, a substantial difference was 
predicted between the two treatment modalities as the individual PAI was 5 or greater. This 
result is in line with increasing evidence suggesting that differential treatment responses are not 





The current study has several limitations. First of all, the relatively small sample size did 
not allow us to build and test the models in separate samples. Using the same sample for testing 
and building the model might lead to a potential risk of overconfidence. Nevertheless, if studies 
are designed to develop and validate prescriptive prediction scores that can be tested in future 
hypothesis-driven confirmatory studies, a smaller sample size might be legitimate [82]. 
Secondly, the results are based solely on self-reports and future studies should also include 
observer ratings. Third, the restricted set of baseline measures is another limitation. Constructs 
such as personality traits or the familiarity with computers have not been assessed but may have 
influenced engagement with the online component. Relatedly, people with a low socioeconomic 
status or senior citizens may not have been well represented in the present study sample. Such 
groups may not have the opportunity to benefit from blended treatment because they may not 
have access to a computer or a smartphone and/or lack the knowledge to use them. As a 
consequence, the restricted sample in the present study limits the generalizability of the results. 
Furthermore, the current study predicts treatment outcome after 12 weeks. Future studies should 
predict long-term treatment outcome [83]. Finally, we have followed a data-driven approach 
instead of a theory-driven approach. Although the two methods should be considered 
complementary [84], a disadvantage of data-driven research is that it is not experiential and 
relying on the data alone might not capture the whole picture. Relatedly, the predictors found 
in the current study need to be validated and replicated in future hypothesis-driven studies. 
In spite of the limitations above, the current study is promising to contribute to the further 
understanding of treatment for depression because it investigates implications for the use of 
blended treatment for patients with depression. Clinical practice should consider factors found 
to play a role in the treatment and processes of change to provide the optimal treatment for each 
individual. For example, the quality of life should be taken into account as these patients may 





based technologies. This interpretation is in line with the notion that more severely depressed 
patients see the availability of an online program between face-to-face sessions as an advantage 
of blended treatment [85]. Furthermore, healthcare utilization should be evaluated prior to 
treatment selection because it can give valuable information about the patients’ needs, treatment 
history and course of illness. In addition, the predictors found to be important in this study and 
in previous studies could be taken into account to make an informed treatment recommendation 
in clinical practice. However, future studies with larger samples and more advanced techniques 
are necessary to validate the current findings and the identified predictors have to be tested 
within clinical routine treatment settings. Moreover, prospective studies need to integrate the 
PAI in the diagnostics process at the beginning of a treatment. 
5. Conclusions 
To conclude with the first aim of the study, two prognostic predictors, namely pre-
treatment symptomatology and treatment expectancy were found. Furthermore, several 
prescriptive predictors were found predicting treatment outcome respective of each of the two 
conditions. Some of our findings are in line with previous research, but other variables such as 
baseline healthcare utilization have not been investigated in this context. The interpretations 
regarding the prognostic and prescriptive predictors need to be tested empirically because they 
are somewhat speculative. Furthermore, this study showed an advantage of model-determined 
treatment allocation to TAU or blended treatment as one third of the participants had a PAI 
larger than 5 which means they would have improved significantly if they had received their 
“optimal” treatment. Although the results need to be validated in future hypothesis-driven 
studies, the predictors found to be important in the current study should be taken into account 
to make an informed treatment recommendation in clinical practice.   
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The current situation of global mental health suggests that mental health issues will 
continue to play a big role in society and the consequences will increase with time. The 
number of people in need of treatment will grow simultaneously with the number of patients 
who do not benefit from first-line treatment as expected. As research has shown, patients vary 
in their illness course and their treatment response. This highlights the need for personalized 
treatments (Cuijpers & Christensen, 2017). In the last years, new advances in psychotherapy 
research and precision medicine have shown promising results for treatment selection. With 
the use of multivariable prediction methods, the identification of prescriptive predictors for 
treatment response is within reach. This doctoral thesis gives an overview of the development 
of process-outcome research and its advances over time. While the Generic Model of 
Psychotherapy is introduced as a theoretical framework to identify variables that have a 
relationship with the psychotherapy outcome, the two studies presented in this thesis use the 
PAI approach to identify prescriptive predictors for different treatments for depression. On the 
one hand, the studies show the feasibility of the PAI approach and on the other hand, they 
shed a light on new treatment approaches like assimilative integration and blended treatment 
for patients with depression. The first study compares CBT to CBT-EE which is a CBT that 
integrates emotion focused principles. Important predictors for each treatment condition are 
identified and model-determined treatment allocation is compared to randomization (see 
Chapter 2.1). The second study uses the same methodology to identify predictors for 
treatment outcome in either TAU or blended treatment and compares model-determined 
treatment allocation to randomization (see Chapter 2.2). In the following, the results of the 
two studies will be discussed in more detail, their limitations will be critically reviewed, and 





3. 1 Determining optimal treatment allocation to CBT vs CBT-EE  
 
 Study 1 identified the most important predictors determining optimal treatment 
allocation to the integrative CBT-EE or standard CBT. In a second step, it investigated if 
model-determined treatment allocation using predictive information results in a better 
treatment outcome for patients with depression. Pre-treatment depressive symptomatology 
was the only prognostic predictor found, thus the only variable that predicted treatment 
outcome in both treatment conditions in the sense that lower pre-treatment depressive 
symptomatology predicts a better treatment outcome, i.e. lower post-treatment 
symptomatology. Regarding the prescriptive predictors, different relevant variables in both 
conditions were found. For the CBT-EE condition, lower age, not being separated or 
divorced, having accomplished a higher education than an apprenticeship, no comorbid 
anxiety disorder, no comorbid axis-II disorder, lower psychopathology, lower self-focused 
rumination, and more hope for improvement predicted a lower post-treatment BDI-II score. In 
the CBT condition, female gender, fewer previous depressive episodes, no recurrent 
depression and a lower current incongruence regarding avoidance motives predicted a better 
treatment outcome.  
 Previous research has found a variety of different predictors due to the heterogeneity 
in research methods and different sets of baseline measures. But the prognostic predictor 
found in this study is in line with multiple earlier studies who have found pre-treatment 
symptomatology to be a prognostic predictor as well. To be exact, previous studies have 
shown that higher pre-treatment severity is related to higher post-treatment symptomatology 
that is defined as worse treatment outcome (Cohen & DeRubeis, 2018; DeRubeis, Cohen, et 
al., 2014; Dinga et al., 2018; Hamilton & Dobson, 2002; van Bronswijk et al., 2018). As 
mentioned in Chapter 2.1.3, baseline measures that have an emotional focus have been 





regulation skills, negative mood regulation, ambivalence over the expression of emotion, or 
self-compassion did not seem to be important to predict treatment outcome in CBT-EE. 
Therapist responsiveness could be held accountable for this in the sense that therapists 
responded differentially to the emotional baseline characteristics that patients displayed 
regardless of treatment condition which then prevented potential differential predictions 
(Stiles, Honos‐Webb, & Surko, 1998). Another explanation could be that both treatment 
conditions can deal equally well with emotional variables meaning that pre-treatment 
characteristics in fact did not have any differential predictive power. With regard to the 
prescriptive predictors of the CBT condition, a study that compared CBT to IPT found female 
gender to be a prognostic predictor of lower depressive symptomatology at post-treatment 
(Huibers et al., 2015). In addition, previous research has found previous depressive episodes 
and recurrent depression to be a prognostic predictor (Blom et al., 2007; Fournier et al., 2009; 
Thase, Reynolds, Frank, & Simons, 1994) whereas it has only predicted treatment outcome 
for CBT in the current study. Moreover, it is surprising that some of the prescriptive 
predictors of the CBT-EE condition, such as age, educational level, and employment have 
been found to be either prognostic or prescriptive in studies that compared CBT, CT or 
treatment with antidepressant medication (Chekroud et al., 2016; DeRubeis, Cohen, et al., 
2014; Fournier et al., 2009).  
 Furthermore, we found that self-focused rumination decreases therapy outcome 
specifically in CBT-EE. As emotion-focused interventions have the goal to change 
maladaptive self-associations, a ruminative self-processing style might make it hard to engage 
in interventions like the two-chair or empty chair exercises (Greenberg, 2002). Hope for 
improvement was also an important predictor in the CBT-EE condition. It is possible that 





activated with emotion-focused techniques because of a possible better outcome in the long 
run (Westermann, grosse Holtforth, & Michalak, 2019, in press).  
 We have included motivational factors in the baseline measures, and in fact, lower 
avoidance incongruence (making less aversive experiences) has found to be an important 
predictor in the CBT condition. Although motivational factors have not been examined in 
earlier research, this finding highlights the relevance to do so. Having stronger aversive 
experiences in life at intake decreases the chance for good therapy outcomes. This is a factor 
that can be crucial in treatment selection and should be acknowledged and further 
investigated.  
 Study 1 shows the feasibility of using the PAI approach to compare two forms of 
CBT, the standard form and an assimilative integration (CBT-EE) which has not been done up 
to date. An advantage of applying PAI research to the field of assimilative integration is that 
the therapists can conduct each of the compared interventions while remaining in his or her 
theoretical framework. The empirical evidence supporting the efficacy of assimilative 
integration is growing and it is common in clinical practice that therapists stay within the 
theoretical framework that they are trained in but use techniques of different approaches that 
potentially utilize other change mechanisms (Castonguay, Eubanks, Goldfried, Muran, & 
Lutz, 2015; Grosse Holtforth et al., 2019; Lampropoulos, 2001). This is in line with Grawe’s 
General Psychotherapy which can be seen as a model of continuous expansion of a therapist’s 
original approach. For Grawe, General Psychotherapy is a guiding principle for clinicians 
with the aim to use all well-established therapeutic interventions in order to achieve the best 
possible treatment result for each individual patient (Grawe, 1999). 
To our knowledge, this is the first study that uses BMA in combination with the PAI. 





that is more than one point lower if they would have received their optimal treatment in 
comparison to their suboptimal treatment. Other studies have found PAIs ranging from 1.6 
(Cohen et al., 2019) up to 8.9 (Huibers et al., 2015). This can be explained by the nature of the 
two treatments compared. As mentioned before, CBT and CBT-EE share the same theoretical 
background and might not differ as much as the treatments that have been compared in earlier 
studies. The same therapist design of the RCT could have lowered the PAI as well. 
Regardless of the small value of the PAI, for 46% of the patients in this sample, a substantial 
difference was predicted between the two treatments as the PAI was 5 or greater.   
3.2 Treatment selection in TAU vs blended treatment 
 
 Using the same approach as in Study 1, Study 2 identified the most important 
predictors that determine optimal treatment allocation to TAU or blended treatment. 
Moreover, model-determined treatment allocation that uses this predictive information was 
compared to randomization. Before we have a look at the prescriptive predictors that predict 
treatment outcome differentially, the two prognostic predictors that were found will be 
discussed. Pre-treatment depressive symptomatology and treatment expectancy were the only 
variables that predicted PHQ-9 scores at 12 weeks. This finding is partly in line with study 1 
and previous research where higher symptomatology before treatment has often been found to 
predict worse outcome in the sense of higher post-treatment symptomatology whereas higher 
expectancy for improvement predicts better outcome, thus lower post-treatment 
symptomatology (Cohen & DeRubeis, 2018; DeRubeis, Cohen, et al., 2014; Dinga et al., 
2018; Friedl, Berger, Krieger, Caspar, & Grosse Holtforth, 2019; Hamilton & Dobson, 2002; 
van Bronswijk et al., 2018). For internet-based treatments, previous research suggests that 
higher pre-treatment symptomatology is often a predictor for higher improvement, thus higher 





studies that have been conducted in previous years are RCTs, this difference might be 
explained by the routine care and effectiveness nature of the E-COMPARED study.    
 In the blended treatment condition, a lower quality of life and being widowed 
predicted worse treatment outcome at 12 weeks. Whereas quality of life is a prescriptive 
predictor here, it has predicted favorable outcome irrespective of treatment condition, thus it 
has acted as a prognostic predictor in previous studies (Huibers et al., 2015). Furthermore, 
healthcare utilization within the four months before starting treatment in the sense of more 
hospital admissions predicted worse treatment outcome. Healthcare uptake may be an 
indicator of a higher somatic or mental burden and may represent a more severe depressive 
symptomatology. This would be in line with earlier research that has found more complex 
cases (e.g. with psychiatric comorbidities and chronic symptoms) and more severe depressive 
symptomatology to predict worse treatment outcome (Blom et al., 2007; Delgadillo, Huey, 
Bennett, & McMillan, 2017; Fournier et al., 2009; Friedl et al., 2019; Thase et al., 1994). As 
this was only found for the blended treatment, it is possible that the highly standardized online 
modules did not sufficiently address comorbid symptoms. For the TAU condition, more 
consultations with a psychiatrist, and more days in a day-time treatment program in a 
psychiatric hospital predicted worse treatment outcome at 12 weeks. This means that patient’s 
healthcare utilization prior to treatment was higher which can speak for a poorer general 
functioning of the patients. As this is a predictor in the TAU condition only, it is possible that 
patient’s functioning was not sufficient to benefit from TAU. 
Study 2 found a PAI of 2.33 indicating that patients could have a PHQ-9 score that is 
on average two points lower if they receive their model-determined optimal treatment as 
opposed to receiving the suboptimal treatment. The results demonstrate the feasibility of 
BMA to use a restricted set of baseline variables to predict treatment outcome. Even though 





2019; Huibers et al., 2015), comparing a face-to-face therapy with blended treatment is a new 
approach. This could be highly useful in increasing treatment response rates in patients with 
depression because the efficacy and feasibility of blended treatments have been shown (Erbe, 
Eichert, Riper, & Ebert, 2017; Kooistra et al., 2016). Blended treatments can offer a solution 
for the problem of accessibility and affordability of treatment which has been mentioned in 
Chapter 1 while it has the ability to promote patient participation and reduce direct medical 
costs (Kenter et al., 2015; Kooistra et al., 2016; Kooistra et al., 2014). Although the PAI 
found here lies within the range of PAIs found in other studies, e.g. 1.35 (Friedl et al., 2019) 
up to 8.9 (Huibers et al., 2015), it is questionable whether they can be compared because of 
the different treatment modalities.   
3.3 Limitations of the studies presented 
 
 Overall, the findings of the studies presented are promising. The results may 
contribute to the further understanding of treatment for depression. Nevertheless, there are 
certain difficulties and limitations in the field of precision medicine and treatment selection. 
In the following, the most important limitations which are generally associated with the 
research presented here, are discussed.  
A common problem in research that plays an essential role in precision medicine and 
treatment selection is small sample sizes. Ideally, the sample size would be big enough to use 
a subsample to build the prediction models and to subsequently use another subsample to test 
and validate the models. The sample size of the two studies presented here did not allow us to 
train and test the models in different subsamples which leads to a potential risk of 
overconfidence. A recent study analyzed the sample size requirements for multivariate 
prescriptive prediction models that guide treatment selection for patients with depression. 





statistical power. Although this is a considerably higher number than the sample sizes in most 
studies, it is important to mention that this suggestion is only applicable to populations whose 
parameters are in the range of the ones used in the study that generated the results. 
Furthermore, smaller sample sizes can be justified if studies are designed to develop and 
validate prescriptive prediction scores that can then be tested in hypothesis-driven 
confirmatory studies. As an example, this is the case for the two studies presented here 
(Luedtke et al., 2019; Petkova et al., 2017). Another problem common in psychotherapy 
research is the generalizability. When building prediction models, we do not know how the 
model would perform if applied to populations that have baseline scores outside the range of 
the populations that were used for building the models. Validation samples are needed to 
solve this issue but as mentioned above, large datasets are required for that.  
Moreover, it is a fundamental problem that so far hardly any consistent predictors have 
been found throughout the years. One possible explanation for this might be therapist 
responsiveness which is defined as a therapist’s behavior that is influenced by emerging 
context and in particular by patient’s behavior and changing characteristics. When therapists 
respond to patient’s requirements throughout the therapy process, they defeat research designs 
of process-outcome research by performing unpredictable and adapting behaviors (Kramer & 
Stiles, 2015). This is why responsiveness makes it impossible to draw causal conclusions in 
research and it undermines conclusions that are drawn based on linear statistics and linear 
reasoning (Kramer & Stiles, 2015; Stiles, 2009; Stiles et al., 1998). Interestingly, DeRubeis 
and colleagues found that the correlation between the measurement of therapy quality and 
outcome is quite small under conditions that are common in psychotherapy research. It 
appears that some patients improve regardless of the therapy quality, and others will not 
improve no matter how good or bad the therapy quality is. As a result, they identified various 





the challenging patient and the intractable patient (DeRubeis, Gelfand, German, Fournier, & 
Forand, 2014). Another explanation may be that research on treatment selection and precision 
medicine has exclusively focused on pre-treatment variables although it may be essential to 
include and investigate the impact of early process variables. Only when a therapy has started 
may patterns appear which predict a relatively consistent positive or negative course. This 
aspect is given more attention in the Generic Model of Psychotherapy and in process-outcome 
research in general. As laid out in chapter 1.2., the “process” is the heart of the Generic 
Model. It is the part that contains early process variables that potentially influence therapy 
outcomes.  
Finally, there is a lack of comparability of the different studies in the field of treatment 
selection. Two reasons can be held accountable for this: (1) different methods and approaches 
to prescriptive modeling are used which result in different outcome measures that may be 
hard to compare and (2) studies use different sets of baseline measures. This leads to a great 
variety of predictors that are found and makes it difficult for clinicians to know what 
predictors to rely on when making a treatment recommendation. 
3.4 The future of treatment selection and precision medicine 
 
The era of treatment selection and the use of prediction algorithms in psychotherapy 
research is still relatively young. With the increase of research done in this field, the 
necessity, as well as the advantages of personalized treatments become more salient than ever. 
We need to limit the number of patients who do not respond to first-line treatments and we 
need to reduce the average time that patients need to recover. If we can manage to provide to 
each patient the treatment that is likely to yield the best result for him or her, we can not only 
reduce the suffering from symptoms of depression but we can ultimately impact the economic 





the previous chapters, accessibility and availability of psychotherapy and pharmacotherapy 
are not always given which is why the limited or costly resources should be well allocated in 
order to result in cost- and time- effectiveness (Cohen & DeRubeis, 2018).  
Another point that needs attention is the methodology that is used to advance the 
clinical utility of treatment selection. Early on, approaches like STS or the Generic Model of 
Psychotherapy have taken into account multiple variables that may influence the treatment 
outcome. Precision medicine focuses on fine-grained individual differences because of the 
great importance of variability in treatment outcomes. What we need is actionable, 
prescriptive information about which patients benefit most from what treatment (Zilcha-
Mano, 2018). This is only possible with the use of multivariable treatment selection 
approaches. Instead of relying on one single moderator, we need to take into consideration the 
overwhelming amount of therapist, patient and setting factors. New statistical methodologies 
like machine learning make this endeavor possible (Cohen & DeRubeis, 2018).    
The present doctoral thesis and the two included studies show several examples of 
multivariable treatment selection and its feasibility. So far, they have failed to have a 
meaningful impact on client care because the identified predictors need to be tested 
prospectively within clinical routine treatment settings. Future studies should evaluate the 
feasibility and the added value of integrating a treatment selection model during the 
diagnostic process at the beginning of psychotherapy. Furthermore, for clinicians to take into 
account the important predictors found in previous studies to make an informed treatment 
recommendation for their patients, future studies with larger samples are necessary to validate 
them first. Another problem of the PAI, other older (e.g. STS) but also newer approaches (e.g. 
machine learning) is that they are atheoretical and have not yet promoted theoretical 
understanding of prescriptive and process-outcome research. It would be important that the 





the Generic Model of Psychotherapy can be helpful. To conclude, not only new 
methodologies are useful when optimizing patient care because newer, updated versions of 
older constructs can be handy, as well.  
3.4.1 New Generic Model of Psychotherapy 
 
The Generic Model of Psychotherapy already exists for over 25 years. It has not only 
acted as a basis for integrating research findings, it has also guided research to deconstruct, 
demystify and integrate clinical practice theories of psychotherapy. That said, it goes beyond 
summarizing findings of particular studies because it can expand to include new aspects of the 
therapeutic process that may be important (Orlinsky, 2009; Orlinsky et al., 2004). The 
Generic Model of Psychotherapy has also been used to guide exploratory psychotherapy 
research that aims to identify emerging patterns of relationships between process and outcome 
(Kolden, 1991).     
With the advances in elaborate statistical methodologies like machine learning and the 
need for personalized treatment selection, one can ask “What role can the Generic Model of 
Psychotherapy play in treatment selection? Will it be able to keep up with the new emerging 
methods?”. In fact, there are some constructs that are not displayed in the model that might be 
of importance. As an example, the Generic Model only depicts linear relationships between 
process and outcome and phenomena like sudden gains (Tang & DeRubeis, 1999) are not 
taken into consideration. Moreover, several constructs that have not gotten much attention 
when the model was constructed and adapted or that have not been researched extensively, 
might have been found to play a role nowadays. Another important point to mention is that 
only very few meta-analyses have been included in the model (Orlinsky et al., 2004). Of 
course, the reason for that is the lack of meta-analyses at that time but nevertheless, they 





been investigated more in the last years are for example therapist repair of alliance ruptures 
(Eubanks, Muran, & Safran, 2018) or premature vs completed termination (Orlinsky et al., 
2004; Swift & Greenberg, 2012).  
3.4.2 The future of precision mental health 
 
To impact client care positively, it is essential to transfer the knowledge gained in 
research to clinical practice. The highest goal should be to translate research findings into 
clinical support tools that therapists can use to make an informed treatment selection. An 
important step in this process is the collaboration of patients and therapists. The needs and 
preferences of clinicians need to be matched with the needs and preferences of patients. 
Furthermore, pre-treatment assessments should include larger sets of variables, even though 
this is not always possible in RCTs. Large databases are available that have collected data 
electronically and could be used more frequently for treatment selection research (Perlis et al., 
2012). More importantly, not only pre-treatment variables but also potential early process 
predictors should be taken into account like it is the case in the Generic Model of 
Psychotherapy. Clinicians need support tools that not only support them with selective 
indication but also with adaptive indication. More recently, person-specific dynamic 
assessments in personalized treatment selection and precision medicine have shown 
promising results although research is still rather scarce. With the use of dynamic 
assessments, it is possible to determine person-specific syndrome structures that provide 
unique information about psychopathology within an individual (Fernandez, Fisher, & Chi, 
2017; Fisher, 2015; Fisher & Boswell, 2016). Moreover, more data should be made available 
to researchers around the world in the sense of open source because, in the long run, patients 
would benefit from sharing resources and results. Last but not least, clinical trials that 





to validate results prospectively against standard allocation schemes (Cohen & DeRubeis, 
2018).  
3.4.3 Implementation of treatment selection in clinical practice  
 
The last essential step for precision mental health to have an impact on client care is to 
test personalized psychotherapy prediction and adaptation tools in clinical practice (Cohen & 
DeRubeis, 2018). This is what the Trier Treatment Navigator (TTN) has been developed for. 
The TTN was developed based on a sample of 1234 patients with affective disorders that have 
been treated in the outpatient clinic of the University of Trier (Lutz, Clausen, & Deisenhofer, 
2019; Lutz, Zimmermann, Muller, Deisenhofer, & Rubel, 2017). The empirical basis for the 
personalized treatment predictions of the TTN is provided by psychometric information that is 
collected from each patient at the beginning of therapy, i.e. the baseline measures. Based on 
this information, similar patients are first selected from the total database of already treated 
patients for a new patient to be treated using the next-neighbor procedure. Therapists then 
receive an assessment of which strategy has been successful with similar patients treated 
before. In addition, therapists receive an overview of potential risk areas the patient might 
have (Lutz et al., 2019). Several therapy process measures provide the basis for this adaptive 
indication. If the observed therapy course deviates from the mean therapy course of the 30 
most similar patients and if the process is crossing the border to a risk area, a warning is given 
that the patient is currently "Not On Track". Besides, clinical support tools are displayed, 
which are related to the respective problems of the patient (e.g. risk/suicidal tendencies, 
motivation/therapy goals, therapeutic relationship, social support and emotion regulation). 
These support tools include treatment recommendations, clinical exercises and sample videos 
for the respective problem area. An RCT that evaluates the effects of the TTN is currently 





The TTN is an important example of how the transfer of research results into daily 
practice can look like. Although we should not jump to conclusions, it may provide an 
opportunity for clinicians to integrate research on personalized treatment selection into their 
clinical work. Both researchers and clinicians have the same goal, namely, to offer patients 
the best possible treatment and to optimize mental health care for people in need of 
psychosocial support. Much work has yet to be done but if the field of precision medicine and 
treatment selection continues to grow as it has in recent years, we have the chance of 
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